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Introduction 
Functional gastrointestinal disorders (FGIDs) are characterized by chronic complaints 
arising from disorganized brain-gut interactions leading to dysmotility and hypersensitivity. 
FGIDs diagnosis is made by symptom-based approach using the corresponding Rome 
criteria. Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are the two most 
prevalent FGIDs, affecting up to 16-26% of worldwide population1,2. However, despite 
these figures, their etiopathogenic mechanisms remain unclear, accounting for the lack of 
diagnostic biomarkers and the paucity of therapeutic options providing satisfactory long-
standing clinical remission3.  
FGIDs are associated with a high prevalence of psychiatric comorbidities, chronic fatigue 
and chronic somatic and visceral pain disorders, rendering substantial social, humanistic 
and direct and indirect health care costs4. Recent observations revealing the presence of 
low-grade mucosal inflammation and immune activation, in association with impaired 
epithelial barrier function5,6 and aberrant neuronal sensitivity come to challenge the 
traditional view of FGIDs as pure functional disorders, and relate the origin to a tangible 
organic substrate that stimulates the search for innovative diagnostic and therapeutic 
approaches. Mast cells (MCs), eosinophils and intraepithelial lymphocytes dominate the 
inflammatory infiltrate in the intestine of FGIDs. MC activation can generate epithelial and 
neuro-muscular dysfunction and promote visceral hypersensitivity and altered motility 
patterns in FGIDs7,8,9, postoperative ileus, food allergy and inflammatory bowel disease 
(IBD)10. This review will discuss the role of mucosal MCs in the gastrointestinal (GI) tract 
with a specific focus on recent advances in disease mechanisms and management in IBS 
and FD. 
The origin, phenotypes, and function of gastrointestinal MCs 
Page 3 of 104
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
4 
 
MCs are long-lived granulated cells derived from bone marrow myeloid-cell progenitors 
(CD34+), under the influence of stem cell factor and interleukin (IL)-4, cytokines that also 
regulate the development of MCs subtypes11. MC progenitor cells (CD34+, CD13+, c-kit+, 
FcεRI-) circulate in low numbers in the blood and migrate to locate in close proximity to 
blood and lymphatic vessels, glands, smooth muscle, and nerves. In the tissue, they remain 
as a homeostatic pool or they complete their differentiation process into mature MCs, as a 
direct consequence of genetic background, and inflammatory or bacterial-derived 
molecules released in the local micro-environment including IL-3, IL-4, IL-9, IL-10, IL-33, 
CXCL12, transforming growth factor-β, nerve growth factor (NGF), and stem cell factor12. 
Intestinal homing of MCs progenitor cells depends mostly on the binding of α4β7 integrin 
with their corresponding adhesion molecules such as cell adhesion molecule-1 or vascular 
cell adhesion molecule-1 on the endothelium, although the CXC chemokine receptor 2, 
expressed on MC progenitors, has been also implicated13. Mature MCs are particularly 
abundant in body barriers, ready for optimal interaction with the local environment. In the 
GI tract, MCs comprise 1-5% of mononuclear cells in the lamina propria and the 
submucosa, and are also found intraepithelial and deep in the muscle and serosal layers. 
Based on the anatomical location, human MCs are classified into mucosal MCs and 
connective tissue MCs, while depending on protease content, MCs are divided in two large 
subsets: MCT, containing tryptase but little or no chymase, and MCTC, containing tryptase, 
chymase, and carboxypeptidase12,13. MCC, which express chymase but little or no tryptase 
also have been described, but they appear to be infrequent12,13. MCT prevail in the intestinal 
and pulmonary mucosa, near T cells, whereas MCTC are found in the skin and lymph nodes, 
in addition to the lung and the gut submucosa11. In the human small intestine, MCT 
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represent ~98% of all MCs in the mucosa and ~13% of MCs in the submucosa are MCT
12
. 
Recently, a new phenotype of MCs expressing tryptase and carboxypeptidase A3, but not 
chymase, has been described in the airway epithelium in asthmatic subjects and in 
esophageal samples of patients with eosinophilic esophagitis14. Heterogeneity of MCs also 
includes differential content in heparin, cytokines, and the receptor for the complement 
C5a, and the trans-differentiation between subtypes12,13. Therefore, location and granule 
content will determine the nature of mediators released to the extracellular milieu, 
accounting for modulation of specific functions in the GI tract11  
MCs have been viewed, for the most part, as effectors of allergy and anaphylaxis and are 
best known for their association with pathological conditions such as asthma. However, the 
advent of MC lines, mouse strains deficient in MCs, and the reconstitution of these strains 
with bone marrow-derived MCs, has greatly facilitated the characterization of various 
aspects of MC function in vivo and their involvement in several disease states by 
interacting with a variety of other cells implicated in physiological and immunological 
responses. In the GI tract, MCs regulate vascular and epithelial permeability, ion secretion, 
angiogenesis, peristalsis, fibrosis and tissue repair, innate and adaptive immunity, bacterial 
defence, chemotaxis, and nociception11. Hence, uncontrolled or dysregulated MC activation 
may interfere with gut homeostasis and generate tissue dysfunction and promote 
inflammation in diverse GI diseases such as food allergy, IBD, postoperative ileus,, 
autoimmune disorders, cancer, and FGIDs11. However, at the same time, MCs are 
indispensable for controlling a wide range of pathogenic infections, and for modulation 
innate and adaptive immune responses15. Indeed, MCs can be intentionally activated to 
enhance protective host responses, including the production of high-affinity antibodies and 
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immunological memory, raising the possibility of incorporating MC activators in vaccine 
formulations to harness the inherent adjuvant activity of MC activation15. 
Regulation and activation of MCs 
The classical and most effective stimulus for MC activation is crosslinking of cell surface-
bound IgE to its high-affinity receptor (FcεRI) by allergen in sensitized individuals16. This 
results in a sequence of phosphorylation cascades and activation motifs that leads to 
intracellular calcium flux, activation of certain transcription factors such as AP-1 (c-FOS, 
v-Jun), MITF and STAT-5, and MC degranulation and cytokine production17. MCs also 
express receptors for IgG (FcγRI), immunoglobulin free-light chains (IgLC), other Ig-
associated receptors, complement fractions, and toll-like receptors (TLRs). Moreover, MCs 
can be activated by neurotransmitters, neuropeptides, growth factors, and hormones (Table 
1), accounting for MC versatility. Upon activation, MCs release newly synthesized (lipid 
mediators and cytokines) and stored (histamine, heparin, proteases) bioactive substances 
contained in cytoplasmic lipid bodies and granules (Figure 1). Secretion is achieved by 
IgE-mediated rapid release of all granule contents by fusion of granules and extrusion 
(anaphylactic degranulation) or by partial or total granule emptying without inter-granule 
fusion (piecemeal degranulation)18. Neuropeptides, cytokines, and microbial products 
induce piecemeal degranulation as frequently seen in diverse diseases, including IBD, IBS 
and FD19.  
Factors and mechanisms underlying MC activation in the gut 
Food antigens as trigger for MC activation  
The majority of FGIDs patients consider their symptoms to be related to meals. For 
example, more than 60% of patients with IBS report the onset or worsening of symptoms 
after meals, within 15 min in 28% and within 3 h in 93% of these patients20,21. Classically, 
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in food allergy, MCs are activated by food antigen-dependent cross-linking of antigen-
specific IgE to FcƐRI. Although some patients with IBS have a higher incidence of atopy22, 
food allergy has not convincingly been associated to FGIDs pathogenesis. Of note, adverse 
reactions to food, including some types of food intolerance, may occur through IgG-
mediated sensitization of MCs but the role for these IgG-mediated immune reactions 
remains to be established20,22. When candidate food antigens are directly applied to the 
duodenal mucosa of IBS patients with suspected food intolerance through an endoscope it 
caused immediate epithelial breaks, increased intervillous spaces, and increased IEL 
numbers in the intestinal mucosa23, and an individualized exclusion diet improved 
symptoms in 74% of patients at 1 year follow-up. The underlying mechanism and the 
potential role for mast cells, requires further study. On the other hand, the response to food 
is also partly regulated by neuroendocrine factors including peripheral serotonergic 
responses24. Although MCs can secrete and synthesize serotonin from tryptophan and 
serotonin is a chemotactic molecule for MCs25, and some adverse reactions to diet in 
FGIDs involve foods containing serotonin, including cheese, meat, soya beans, cereals, nuts 
and vegetables26, the role of MCs in such responses, if any, is mostly ignored. Finally, spice 
intake correlates directly with the likelihood of developing IBS in females27. Spicy foods 
contain capsaicin, the natural ligand of transient receptor potential vanilloid 1 (TRPV1) 
receptors on nociceptive afferent C-fibers. The increased density of sensory fibers 
expressing TRPV1 receptors reported in patients with FGIDs and visceral 
hypersensitivity28, the genetic polymorphism of TRPV1 gene in FD29, the potential TRPV1 
sensitization in IBS patients30, the close proximity of MCs to TRPV1 expressing sensory 
nerve fibers, and the ability of capsaicin to modulate MCs31 all suggest that transmission of 
pain signals, including those generated by spicy foods, may be enhanced in FGIDs. In 
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contrast, desensitization of afferent terminals by a high capsaicin diet seems also plausible, 
as one study reported beneficial effects on abdominal bloating and pain in response to the 
ingestion of encapsulated red pepper for 6 weeks in IBS32. 
The role of infections 
Post-infectious (PI)-FGIDs represent common entities in daily clinical practice. Infectious 
gastroenteritis is associated with an increased risk for FD and IBS, however the 
mechanisms leading to chronicity remain unknown33. MCs are potential regulatory linkers 
between innate and adaptive immunity and have been demonstrated to play critical roles in 
host defense, participating in effective immune responses to a number of bacterial, 
parasitic, viral and fungal pathogen products15. Antibody titers against bacterial flagellin 
are increased in IBS patients and are even higher in PI-IBS34. Recently, increased mucosal 
Ig production and up-regulation of germline transcripts and Ig genes have been identified in 
diarrhea predominant IBS (IBS-D) together with increased proximity between MC and 
plasma cell, suggesting MC activation by Ig35. Whether FGIDs individuals may become 
sensitized to food and microbial antigens during an acute infection and subsequently 
develop antibodies that will activate MCs upon antigen exposure remains to be established.  
The role of stress 
Chronic stress may also lead to MC activation. In preclinical studies, several types of 
stresses and stress mediators such as corticotropin releasing hormone (CRF) and related 
peptides have been shown to modulate ion and water secretion as well as intestinal and 
colonic paracellular and transcellular permeability, primarily via nerve-MC interactions36,37. 
Similarly, stress-induced rectal hyperalgesia could be prevented and reversed by 
administration of a MC stabilizer38. Other studies have confirmed and extended this 
paradigm to the human intestine. Santos et al. showed that a cold stress increased jejunal 
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MC tryptase and histamine release along with intestinal water secretion39, and intestinal 
permeability, with larger responses in women with moderate levels of background stress40. 
CRF has been shown to enhance transcellular uptake of macromolecules in human colonic 
mucosa via CRF-R1 and CRF-R2 receptors located on subepithelial MCs41. More recently, 
acute psychological stress (public speech) has been shown to increase small intestinal 
permeability in humans42. This effect could be reproduced by peripheral administration of 
CRF, and blocked by the MC stabilizer disodium cromoglycate (DSCG). Preclinical 
models showed that chronic stress can induce substance P (SP) release by efferent nerves in 
the periphery, leading to CRF expression and release by intestinal eosinophils. Eosinophil-
derived CRF was then capable of activating MCs resulting in jejunal epithelial barrier 
dysfunction43. SP, NGF and sex steroids also induce the release of vasoactive mediators 
from MCs, contributing to chloride secretion, barrier dysfunction, hyperalgesia, diarrhea, 
inflammation and motility changes44,45.  
MC infiltration in the GI tract in FGIDs  
Since the description by Weston et al in 1993 on the infiltration of the terminal ileum by 
MCs in IBS46, numerous studies evaluated MC numbers in the gastrointestinal mucosa of 
FGIDs (Table 2). It is interesting to note here that the presence of low-grade intestinal 
inflammation in the gut of these patients also involves an increase in intraepithelial T 
lymphocytes, and less consistently, enterochromaffin cells, plasma cells, B lymphocytes, 
neutrophils, and other immunocytes47,48.  
MCs have been identified by metachromatic stains such as Giemsa or toluidine blue, but 
these methods have been replaced by immunohistochemistry (antibodies for c-kit (CD117) 
or tryptase)49,50,51 because it is more sensitive and specific. MC counts are comparable with 
both stains, yet CD117+ cells display a more stable membranous staining whereas tryptase+ 
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cells display cytoplasmic staining that could be influenced by cell degranulation52. FGIDs 
biopsies contain singly dispersed MCs with no aggregates52. When elevated MC counts are 
detected, it may be helpful to exclude systemic mastocytosis by staining for the low-affinity 
receptor for interleukin-2 (CD25)52. A reference range for significant increased MC counts 
is still lacking. This is partly due to the absence of agreement and standardization on the 
methodology used to count MCs, to differences in patient and control selection, inter-
individual variation, location of the biopsy, the relatively small cohort numbers for the 
majority of individual studies, and to other uncontrolled potential confounding factors 
(Table 3) [see Nasser et al for a detailed review]. The great variation in reporting mean 
mucosal MC numbers in the GI tract makes the interpretation of discriminatory cutoff 
values very complicated and currently un-interpretable according to some pathologists53. 
MC counts have been found to be normal, increased or decreased in IBS (Table 2). 
However, although the numbers vary across studies and segments, the analysis of more 
than one thousand IBS biopsies detects a mean, modest 1.2-2.5 fold increase in MC 
numbers throughout the entire gastrointestinal tract54,55. This is also true for cases of 
chronic undefined diarrhea, mostly studied in the upper small bowel and left colon, to the 
point that some pathologists debate the convenience of coining the term mastocytic 
enterocolitis for this clinical-pathological association56. A significant finding is that 
mucosal MC “hyperplasia”, when present, is not limited to the lower small intestine57-58 and 
colon59,60 but also involves the duodenum61, the jejunum62, and the rectum63. While there is 
discrepancy in IBS, available studies in FD reveal that MC numbers are significantly 
increased in the antrum and corpus of H. pylori negative FD64,65, and in the duodenum of 
FD patients (Table 2)9,61,66,67. Moreover, increased MCs have been recently reported in the 
esophagus of patients suffering noncardiac chest pain68. Even so, it is hard to dismiss the 
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physiological relevance of such “modest” increases because, on one side, similar 
incremental changes in leukocyte counts in circulating blood occur in infectious and 
inflammatory conditions, and on the other side, the magnitude of cell change is enormous if 
we consider the total mucosal surface of the gastrointestinal tract.  
When evaluating MCs in IBS subtypes, some studies show that MC hyperplasia is more 
common in IBS-D69,70 and in non-PI IBS71 than in other subtypes, though in many other 
studies this is not the case72,73,74. In contrast, MCs are increased similarly in gastric biopsies 
in PI-FD and nonspecific FD75. Moreover, others found MC numbers decreased in the 
descending colon of diarrhea and alternating predominant IBS, but not constipation 
predominant IBS compared to health51. There is also some indication that MC numbers 
remain increased compared to both non-PI IBS and controls, three years after Shigella 
infection73. Although not the scope of this review, an increased number of MCs has been 
reported in the colorectal mucosa, in the lamina propria and in the submucosa from patients 
with Crohn’s disease and ulcerative colitis10. 
The role of gender differences in MC number is unclear. Several lines of evidence indicate 
that gonadal steroids are involved in gender-related differences in tissue MC infiltration in 
the colon. This difference in the number of MCs has been described in a variety of tissues 
from rodents, such as skin, myocardium and rat colon. When specifically analyzed, some 
authors found increased MC counts in the terminal ileum, ascending and descending colon, 
and rectum of female vs male controls57,60,74 , with females showing 43% increase in the 
area occupied by MCs7, similar to observations in patients with chronic undefined 
diarrhea53, while others do not51,60,63. These data raise the hypothesis that gender-dependent 
differences in immune responses are involved in the observed higher prevalence of IBS in 
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females, in the described gender-related differences in IBS pathophysiology, and in the 
known effects of the menstrual cycle in the modulation of rectal sensitivity76. 
Differences in MC numbers in the jejunum, cecum, colon, or rectum of IBS are not 
attributable to age, stress and cortisol levels, anxiety or depression, or duration of the 
disease51,60,62,69. Although disputed, it seems that changes in MC counts cannot easily be 
explained by differences in bowel preparation7,48. The role of diet on MC counts remains to 
be established. Thus, the diagnostic utility of routine MC stains in gastrointestinal biopsies 
remains unclear and requires further investigation.  
MC activation in the gastrointestinal tract in FGIDs 
MC activation in the gastrointestinal tract may be evaluated by: 1-Morphological analysis, 
most commonly by checking ultrastructural characteristics of piecemeal or anaphylactic 
degranulation on transmission electron microscopy (TEM); 2-Measuring the spontaneous 
or stimulated release of mediators in tissue, intestinal fluid, and blood, most commonly 
tryptase and histamine, and less often hexosaminidase, carboxypeptidase A, heparin, 
chromogranin A, leukotriene E4, prostaglandin D2, and prostaglandin 9α,11βPGF2, and 
methylhistamine in urine, and; 3-The expression of related genes and proteins in the 
mucosa (Figure 2).  
Based on TEM studies, it has been shown that MCs display higher activation rates in the 
cecum and rectum in IBS-D, and that activation rates increase even more when nerve-MC 
distance is less than 2 µm59. Moreover, MCs located within 5 µm of nerve fibers were 3.1-
times more frequent in the descending colon of IBS than in controls, and there was a 150% 
increase in the number of degranulating MCs7. Furthermore, the ileal and colonic density of 
neuronal specific enolase, SP, and 5-hydroxytryptamine positively stained nerve fibres 
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increased and appeared in clusters, surrounding an increased number of MCs with no 
differences between PI and non-post-infection IBS patients73,77. 
Supernatants of mucosal biopsies of IBS patients contain increased concentrations of 
histamine, serotonin, trypsin, tryptase, prostaglandin E2, other proteases, and 
cytokines7,78,79,80. Moreover, jejunal luminal tryptase release was 5-times higher62 and the 
expression of both tryptase mRNA and protein enhanced in jejunal tissue8 in IBS-D, while 
serum tryptase remained unaltered. Tryptase protein expression was also higher in both 
postinfectious FD and nonspecific FD gastric biopsies64.  
It is interesting that λIgLC+ MCs but not IgE or IgG+ MCs are reduced in the colon of 
IBS51. This finding, together with the description of elevated serum concentrations of λ and 
κ IgFLC in IBS81, suggests that Ig light chain-mediated MC activation may be associated 
with IBS.  
Taken together, evidence indicates that the activity of MCs rather than an increased number 
is essential in the pathophysiology of FGIDs, a point that has been recently raised by 
several experts in the field.  
Linking MC infiltration and activation in the gastrointestinal tract with clinical 
manifestations in FGIDs 
Role of MCs in visceral hypersensitivity and motility changes: motor and neuronal 
activation and sensitization 
In the human gut, MCs lie in close proximity to gastrointestinal mucosal sensory nerve 
fibers containing neuropeptides, including visceral afferents expressing TRPV1 receptors82. 
This close spatial association, when coupled with MC activation, has been suggested to be 
of functional relevance for neuromuscular function and altered pain perception in response 
to insults such as infections, stress, and emotions in FGIDs47,83. Indeed, afferent innervation 
Page 13 of 104
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
14 
 
of enteric MCs can trigger the release of histamine and mast cell protease II, mediators that 
act in a paracrine manner to elevate the sensitivity of spinal afferent terminals84. The use of 
supernatants obtained from biopsies allows studying the effect of these mediators on 
neuronal activation and sensitization. Injection of IBS-derived supernatants into rat 
mesenteric arteries evoked a marked increase in afferent nerve discharge, whereas injection 
of control supernatants had no effect79. In addition, IBS-dependent excitation of dorsal root 
ganglia (DRG) was inhibited by histamine H1 receptor blockade and serine protease 
inactivation78, underscoring the role of MC mediators in neuronal activation. These 
findings were confirmed by Buhner et al. who reported that IBS biopsy supernatants, but 
not those of healthy controls, significantly increased the spike discharge of human 
submucosal neurons. This effect was inhibited by histamine receptor (H1-H3) antagonists, 
5-HT3 receptor antagonist and protease inhibition80. Moreover, supernatants from 
hypersensitive IBS patients caused stronger activation of guinea pig enteric and mouse 
DRG neurons compared to supernatants of normosensitive patients85, indicating that 
neuronal activation responses in vitro correlate with the individual pain threshold pressure 
values. Others showed that intracolonic infusion of IBS supernatants, but not controls, 
caused increased nociception in response to colorectal distention in mice, an effect that 
could be prevented by a serine protease inhibitor and was absent in neurons lacking 
functional protease-activated receptor-2 (PAR2)79. More recently, Cenac et al. showed that 
colonic biopsies from IBS patients contain increased levels of PUFA metabolites, these are 
endogenous TRPV4 agonists, compared to healthy subjects and these increases correlated 
with pain and bloating scores86. PUFA metabolites extracted from IBS biopsies or colons of 
mice with visceral hypersensitivity activated mouse sensory neurons in vitro, by activating 
TRPV4, an effect that could be prevented by siRNA knockdown of TRPV486. Finally, 
Page 14 of 104
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
15 
 
application of supernatants on muscle strips evoked excitatory cholinergic longitudinal 
muscle contractions of the guinea pig ileum, an effect that was not dependent on serotonin, 
proteases or histamine but was (partially) mediated by TRPV1, purinergic P2X receptors 
and prostanoid receptors87. Ballestra et al speculate that afferent nerve activation may 
induce myenteric cholinergic depolarizations, leading to altered motor function (Figure 3).  
Besides increased neuronal activation, supernatant of biopsies from IBS patients also has 
the capacity to potentiate sensory nerves. In a recent, elegant study, murine DRG neurons 
were incubated overnight with supernatants of submucosal colonic biopsies of IBS. Patch 
clamp recordings the next day revealed that the intrinsic excitability of the colonic 
nociceptive DRG neurons was increased by IBS-D supernatants. This increased excitability 
was not observed in DRG neurons lacking PAR-288. Finally, incubation of a neuronal cell 
line or rat primary myenteric neuron cultures with mucosal biopsy supernatants from IBS 
also induced long-lasting neuroplastic changes as reflected by increased NGF-dependent 
neuronal sprouting77.  
Together, these preclinical data consistently indicate that the mucosa and submucosa of IBS 
patients contains increased levels of various MC mediators that have the potential to 
activate and potentiate intrinsic and afferent neurons, thereby l ading to increased visceral 
pain perception and altered motor function that may cause diarrhea or constipation as a 
result of excessive segmental contractile colonic motor activity (Table 4). Of note, the use 
of human supernatants on animal models or isolated neurons may not completely reflect 
human physiology as MCs and enteric neurons exhibit species specificity in mediator 
release mechanisms and receptor profile16. To further assess the functional relevance and 
specificity of supernatant-mediated activation of nerve endings in the gut, it may be of great 
interest to perform live-imaging of MC-nerve signaling in human preparations or to 
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perform confocal endomicroscopy. The latter has recently been used to identify suspected 
food intolerance in IBS patients23. 
Role of MCs in the regulation of intestinal barrier function: secretion and permeability  
MCs contribution to barrier function was first described in animal studies in which 
increased ion secretion and transepithelial transport of macromolecules was reversed with a 
MC stabilizer89. In humans, stress induces the release of MC mediators (tryptase, 
histamine) to the intestinal lumen39 and increases intestinal permeability, which can be 
reversed by oral DSCG42. Stress can severely impact on barrier function and favour 
intestinal disease, as might be the case for FGIDs. IBS and FD patients experience high 
levels of anxiety, depression and stress3 and intestinal permeability, as measured by probe 
excretion assays, has been found altered, primarily in PI-IBS and IBS-D90. The mechanisms 
underlying epithelial barrier alterations are not fully understood, but disruption of the 
proteins that seal the paracellular space seems to play a role. Actually, in IBS, the 
expression of several tight junctions (TJ) proteins is reduced compared to controls and, in 
IBS-D, this reduction correlates with MC activation and with common clinical symptoms91. 
In FD, the altered expression of cell-to-cell adhesion proteins also correlates with impaired 
duodenal integrity and with mucosal inflammation9. MCs proximity to the epithelium 
facilitates tryptase activation of PAR-2 receptors on the basolateral side of enterocytes, 
leading to redistribution of TJ and increased paracellular permeability to macromolecules92. 
Other mediators released by MCs upon activation, such as histamine, chymase and 
prostaglandin D2, regulate epithelial chloride and water secretion and permeability93,94. 
MC-mediated intestinal barrier alterations have been also related to neuropeptides, 
neurotransmitters, hormones (vasoactive intestinal peptide, SP, NGF, estrogen, estradiol), 
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and inflammatory mediators (tumor necrosis factor-α, interferon-γ and cytokines) released 
by other immunocytes93 (Figure 4). 
Role of MCs in IBS cardinal manifestations 
MCs in close proximity to nerves in the descending colon were significantly correlated with 
severity and frequency of abdominal pain/discomfort7. In another study, mucosal MC 
infiltration was significantly associated with abdominal bloating frequency and with 
symptoms of dysmotility-like dyspepsia74. In contrast, in IBS, there was no correlation 
between severity or frequency of abdominal pain/discomfort and lamina propria area 
occupied by MCs, release of tryptase and histamine, and number of degranulated MCs per 
field7,57. IBS-D patients with rectal hypersensitivity, according to the maximally tolerable 
pressure to barostat distention, showed significantly lower counts of MCs in the terminal 
ileum, ascending colon and rectum in one study57. Park et al speculated that this 
counterintuitive finding was related to tissue desensitization by MCs mediators57. More 
recently, Braak et al found no correlation between the sensory thresholds to barostat 
distention, abdominal pain, bloating, urgency, incomplete evacuation, hard stools, loose 
stools, frequent and decreased bowel moments and flatulence and MCs counts in the 
colon51. An association between duodenal and antral MCs with pain, and postprandial 
distress syndrome, respectively, has been shown in children with FD67. 
Impaired intestinal permeability, and the expression of TJ proteins has been shown to 
correlate with pain/discomfort and/or bowel habit90,91,95,96. Interestingly, tryptase mRNA 
and protein expression in the jejunum of IBS-D patients correlated with stool frequency and 
consistency but not with abdominal pain, whereas the correlation with MC number was 
poor91.  
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Cecum MC counts correlated significantly with the fatigue and depression scores in IBS60, 
and in some studies there is a tendency or an association between depression and state of 
anxiety scores and the number of MCs in patients with IBS-D57. A significant correlation 
with antral mast cell densities with anxiety, depression and somatization has been reported 
in children with FD67. Moreover, the degranulation of MCs in the duodenum appears to be 
highly sensitive and specific for the identification of adult FD patients as shown by 100% 
sensitivity and specificity indicated by an area under the ROC curve of 1.0 for the optimal 
degranulation rate cutoff values of 30.2% at the duodenal bulb and 36.8% at the descending 
part of the duodenum66. 
Taken together, these findings suggest that interactions between the MCs and the enteric 
and brain-gut neural networks could be of importance in symptom perception in at least a 
subgroup of patients with FGIDs. 
Targeting MCs: implications for treatment of FGIDs 
The MC stabilizer DSCG abolished the effect of acute psychological stress on small bowel 
permeability in human subjects42. Aside from experimental studies demonstrating the 
efficacy of several MC inhibitors to decrease colonic hypersensitivity, in humans, a number 
of uncontrolled observations56, and open clinical studies with DSCG, in doses between 
600-1800g/day, suggest its clinical benefit for chronic persistent diarrhea97, allergic 
enteritis98, FD99, and IBS100,101,102. However, these studies had several limitations including 
poor design, small sample size, and selection bias. Likewise, ketotifen has been recently 
proven to increase the sensory threshold, leading to improved visceral perception, 
especially in the hypersensitivity IBS group103. Although preliminary, there is some 
indication of the clinical benefit of ketotifen and the tryptase inhibitor APC 2059 in 
ulcerative colitis104,105. Our group has recently finished an open trial (awaiting publication) 
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and a consecutive double-blind, placebo controlled, clinical assay, with prolonged (6 
months) oral administration of DSCG, with promising results in the control of main clinical 
manifestations in IBS-D patients (Gastroenterology 2015;148 (Supl 1):S-494). In addition, 
small studies have shown improvement in gastrointestinal symptoms with DSCG therapy in 
systemic mastocytosis106. However, the mechanisms by which MC stabilization could 
interfere with IBS clinical response have not been clearly delineated.  
Other interventions that block the effects of MC mediators and improve GI symptoms 
should be considered. In this sense, anti-inflammatory treatment with mesalazine appeared 
to show improvement in symptom perception in unselected IBS patients in a small proof-
of-concept randomized, double-blind, placebo-controlled trial, in which, in addition, a 36% 
decrease in MC numbers, and a reduction of the number of total immune cells, and T cells 
was observed in the colonic mucosa107. However, two subsequent large clinical trials differ 
in the clinical benefit of mesalazine in IBS108,109, and the effect of mesalazine on MC 
counts and degranulation not confirmed109. Furthermore, there was no effect of mesalazine 
on 5-HT containing enterochromaffin and CD68 cell numbers, although, there was 
significant increase in CD3 count in the mesalazine group109. In further reinforcing the role 
of MC activation in the origin of FGIDs manifestations, it is important to note that 
heartburn, cramping, nausea, abdominal pain and diarrhea are the second most common 
complaint of patients with mastocytosis, and that H2-histamine receptor antagonists have 
been quite effective in controlling these symptoms56,98,110. A recent proof-of-principle 
clinical trial confirmed the clinical relevance of these findings showing improvement of 
abdominal pain and global relief by the H1R antagonist ebastin in IBS patients 
(Gastroenterology 2013;144 (Supl 1):S-160). Palmitoylethanolamide and other inhibitors of 
cannabinoid receptors seem efficacious in controlling pain, motor disturbances and 
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inflammation in animal models through modulation of neuronal and non-neuronal cells, 
including MCs111,112. Slow-release of vitamin C may be also helpful as it increases 
degradation of histamine; and inhibits MC degranulation; in doses not superior to 750 
mg/day110. Natural flavonoids (fisetin, kaempferol, quercetin, rutin, luteolin,..) and the 
active alkaloid berberine inhibit the mediator release of MCs in vitro113 and protect 
intestinal epithelial barrier114. While some of these products have shown to be useful in 
cardiovascular health115 and cancer116, their clinical efficacy in FGIDs has not been 
established. There is some evidence of symptomatic response to specific diets in FGIDs, 
such as low FODMAP and gluten-depleted food20. However, there is no support for the role 
of MCs in this symptomatic response with the exception of the benefit after individualized 
exclusion of foods in FGIDs suffering food allergy. 
Finally, the development of more specific and safe blockers or modulators of IgE, IgG or 
other activation pathways of MC activation, including pathways involved in the selective 
release of mediators, may offer therapeutic advantages, although their benefit remains to be 
established.  
Conclusion 
Current evidence implicating MCs in the pathogenesis and pathophysiology of FGIDs, 
particularly in IBS, and the contribution of their activation and released mediators to the 
development of cardinal manifestations, such as epigastric and abdominal pain, and altered 
defecation is robust, and supports the targeting of MCs in the management in FGIDs. 
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Key points 
• Mast cells play a central pathophysiological role in IBS and possibly in FD, 
although not well defined. 
• Increased mast cell activation is a common finding in the mucosa of patients with 
FGIDs. 
• There is a need to implement standardized methods to count mast cells in the 
gastrointestinal mucosa, and to establish reference ranges of normality.  
• Evaluation of spontaneous and stimulated mast cell function and activity on 
gastrointestinal samples is recommended when available. 
• More studies are required to fully understand the implication of mast cells in the 
origin of clinical manifestations of these disorders. 
• Treatment with mast cell stabilizers offers a reasonably safe and promising option 
for the management of those IBS patients non-responding to conventional 
approaches, though future studies are warranted to evaluate efficacy and indications. 
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Table 1. Triggers of mast cell activation (modified from117) 
Type of stimuli Type of molecule Molecule/stimuli 
Immune Immunoglobulins IgE, IgG, free light chain-Ig 
(+antigen) 
 Other  C3a, C5a, IL-4, IL-6, IL-9, IL-
10, TNF-α, IFN-γ 
Non-immune Neurotransmitters Acetylcholine, Dopamine, 
Serotonin, Epinephrine, 
Histamine 
 Neuropeptides SP, VIP, HRP, CGRP, SS, NT, 
Bradykinin 
 Hormones ACTH, CRF, PTH, Ucn, 
Estradiol 
 Growth factors NGF, SCF, TGF-β, FGF-2, 
VEGF, PD-ECGF 
 Biological LPS, Peptidoglican, 
Micobacterium 
 Physico-chemical NO, osmotic, thermal, pH, 
humidity, trauma, pressure, 
hypoxia, radiation, free radicals 
Ig: immunoglobulin; IL: interleukin; C3a: complement component 3a; TNF-α: tumor 
necrosis factor alpha; IFN-γ: interferon gamma; SP: substance P; VIP: vasoactive intestinal 
peptide; HRP: histamine-releasing peptide; CGRP: calcitonin gene-related peptide; SS: 
somatostatin; NT: neurotensin; ACTH: adenocorticotropin hormone; CRF: corticotropin 
releasing factor; PTH: parathormone; Ucn: urocortin; NGF: nerve growth factor; SCF: stem 
cell factor; TGF-β: transforming growth factor beta; FGF-2: fibroblast growth factor-2; 
VEGF: vascular endothelial growth factor; PD-ECGF: platelet-derived endothelial cell 
growth factor; LPS: Lipopolysaccharide; NO: nitric oxide. 
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Table 2. Studies describing mast cell infiltration and activation in FD and IBS and potential 
correlation with symptoms. 
Condition and 
number of 
subjects 
Site of 
biopsy 
Mast cell 
numbers 
Mast cell  
detection  
Mast cell 
mediators  
Correlation 
with 
symptoms 
Referenc
e 
141 FD and 39 
controls 
Duodenum Increased counts 
Toluidine 
blue 
staining 
NA NA 66 
15 FD and 15 
controls 
Duodenum Increased 
Anti- 
tryptase 
NA NA 9 
19 FD and 19 
controls 
(pediatric) 
 No change 
Anti- 
tryptase 
NA 
No correlation 
between 
permeability 
and mast cell 
density 
118 
65 H. PYLORI -
negative FD 
(pediatric) 
Gastric body 
and 
duodenum 
 
Anti- 
tryptase 
NA 
Headache was 
associated 
with high 
mast cell 
counts in the 
gastric body 
and 
duodenum 
65 
51 FD, 20 IBS-D 
and 21 IBS-C 
and 48 controls 
Duodenum 
Increased counts 
in IBS-C and 
IBS-D and trend 
for increase in 
FD 
Anti-CD-
117 
NA NA 61 
62 FD (33 
Helicobacter 
pylori positive, 
29 H. pylori 
negative and 29 
H. pylori 
positive 
inflammatory 
control subjects 
and 20 controls, 
Antrum and 
corpus 
Increased in H. 
pylori negative 
and positive FD 
samples in 
antrum and 
corpus 
Anti- 
tryptase 
NA NA 64 
225 patients with 
non-ulcer 
dyspepsia 
Antrum 
31 (13%) were 
found to have 11 
or greater mast 
cells per high-
Alcian 
blue 
staining 
NA NA 119 
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power field 
Total of 101 IBS 
and 23 controls, 
for IHC: 15 
controls; 15 IBS-
C; 14 IBS-D 
Descending 
colon 
Increased counts 
Anti-
tryptase 
NA NA 77 
13 IBS-D, 8 
IBS-C and 10 
controls 
(pediatric) 
Ileum, right 
colon and 
left colon 
No change in 
numbers but 
mast cells in 
closer proximity 
to nerves in IBS 
(MC-NF/mm2) 
Anti-
tryptase 
NA 
Abdominal 
pain 
correlated 
with 
MC/mm2 in 
the ileum and 
MC-NF/mm2 
in the right 
colon 
120 
49 IBS-D and 30 
controls 
Jejunum 
Increased counts 
in non-atopic 
IBS 
Anti-CD-
117 
NA NA 35 
100 IBS and 100 
controls 
Colon, 
ileum, 
duodenum 
and stomach 
No change 
Anti-CD-
117 and 
anti-CD-
25 
NA NA 52 
55 IBS-D and 18 
controls with 
lactase 
deficiency 
Sigmoid 
colon, 
ascending 
colon and 
terminal 
ileum 
increased counts 
in the terminal 
ileum, ascending 
and sigmoid 
colon 
Anti-
tryptase 
NA 
Anxiety 
scores were 
associated 
with mast cell 
counts in 
sigmoid 
colon, 
ascending 
colon and 
terminal 
ileum.  
Visceral 
sensitivity 
(i.e. decrease 
in urgency, 
discomfort/pai
n threshold) 
was increased 
in patients 
with high 
mast cell 
density in the 
terminal ileum 
121 
22 IBS-D and 21 
controls 
Rectum 
Increased counts 
in IBS-D 
Anti-
tryptase 
NA 
Mast cell 
counts did not 
correlate with 
122 
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IBS 
symptoms 
including 
abdominal 
pain; Mast 
cell counts 
correlated 
with 
substance P 
and VIP in 
women but 
not in men 
83 D-IBS, 49 
UC (28 in 
remission and 21 
mildly active 
UC), and 25 
controls 
Ascending, 
transverse, 
descending, 
and sigmoid 
colon 
Increased counts 
in patients with 
D-IBS, UC in 
remission, and 
mildly active UC 
Anti-
tryptase 
NA NA 123 
51 IBS, 49 
quiescent IBD 
(31 CD and 18 
UC) and 27 
controls 
Caecum 
increased in 
patients with 
IBS, CD or UC 
(no difference 
between patients 
between patients 
with or without 
IBS-like 
symptoms 
Anti-CD-
117 
NA NA 124 
16 IBS-D and 7 
controls 
Rectum No change 
Anti-
tryptase 
Increased 
tryptase 
release 
Mast cell 
counts 
correlated 
with intestinal 
permeability 
125 
45 IBS-D and 30 
controls 
Jejunum Increased counts 
Anti-CD-
117 
Increased 
tryptase 
mRNA 
and 
protein 
Tryptase 
mRNA 
expression but 
not mast cell 
counts 
correlated 
with stool 
frequency and 
consistency in 
IBS-D 
patients; 
tryptase 
protein 
expression 
correlated 
CLDN2 
protein 
overexpressio
n and 
increased 
8 
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OCLN 
cytoplasmic 
staining 
16 IBS-D, 21 C-
IBS and 11 
controls 
Descending 
colon 
Increased counts 
in IBS-C but not 
IBS-D 
Anti-
tryptase 
NA 
Mast cell 
counts of IBS 
but not 
controls 
correlated 
with the 
twitch 
enhancement 
evoked by 
biopsy 
supernatants 
87 
34 IBS and 15 
controls 
Rectum Increased counts 
Anti-CD-
117 
Increased 
tryptase 
release 
IBS severity 
correlated 
with colonic 
permeability, 
mast cell 
counts and 
tryptase 
95 
4 IBS-C, 11 IBS-
D, 8 IBS-A and 
15 controls 
Colorectum No change 
Anti-
tryptase 
NA NA 126 
11 IBS-D and 14 
controls 
(pediatric) 
Rectum No change 
Anti-
tryptase 
and anti-
CD-117 
NA NA 127 
15 IBS-D, 15 
IBS-C, 36 IBS-A 
and 20 controls 
Descending 
colon 
decreased mast 
cell counts 
Anti-CD-
117 
NA 
No correlation 
between the 
the number of 
mast cells and 
abdominal 
pain or 
sensory 
thresholds of 
first sensation, 
urge or 
discomfort 
and 
51 
25 IBS-D and 23 
controls 
Jejunum Increased counts 
Anti-CD-
117 
Increased 
tryptase 
mRNA 
Tryptase and 
SCF 
correlated 
with tight 
junction ZO 
protein 
expression. 
Bowel 
frequency and 
91 
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stool 
consistency 
correlated 
with both the 
number of 
mast cells and 
tryptase 
mRNA 
expression,  
and with the 
expression of 
ZO proteins 
12 IBS-C, 13 
IBS-D and 12 
controls 
Desce ding 
colon 
Increased counts 
Anti-
tryptase 
Increased 
serotonin, 
histamine 
and 
tryptase 
release 
irrespectiv
e of bowel 
habit 
5-HT release 
correlated 
with mast cell 
counts and the 
severity of 
abdominal 
pain 
128 
60 IBS and 22 
controls 
Rectum and 
descending 
colon  
decreased mast 
cell counts in 
rectal biopsies 
Anti-
tryptase 
and anti-
CD117 
Lower 
release of 
tryptase, 
slight 
increase in 
histamine 
release 
The severity 
of abdominal 
pain was not 
correlated 
with mast cell 
counts; no 
correlation 
between 
abdominal 
pain and 
spontaneous 
histamine or 
tryptase 
release 
103 
13 IBS-D, 8 
IBS-C, 4 IBS-A, 
10 active CD and 
18 controls 
Descending 
colon 
Increased counts 
in IBS-D but not 
in IBS-C 
Anti-CD-
117 
Increased 
trypsin-
like 
protein  
NA 129 
27 IBS-D, 21 
IBS-C, 12 MC 
20 UC, and 24 
controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
NA 
Mast cell 
counts in IBS 
patients was 
associated 
with 
abdominal 
bloating 
frequency and 
with 
symptoms of 
dysmotility-
like 
dyspepsia, but 
74 
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not ulcer-like 
dyspepsia 
7 IBS-D, 4 IBS-
C and 4 controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
Increased 
tryptase 
and 
histamine 
release but 
not 
serotonin 
Association 
between the 
number of 
mast cells and 
the 
corresponding 
supernatant-
evoked spike 
frequency. 
Tryptase, 
histamine and 
serotonin 
concentrations 
all correlated 
with the 
supernatant-
evoked action 
potential 
discharges. 
80 
8 IBS-D, 8 IBS-
C, 7 IBS-A and 
22 controls 
Rectosigmoi
d 
Increased counts 
Anti-CD-
117 
NA 
c-kit+ cells 
correlated 
with maximal 
VAS pain 
score 
28 
50 IBS, 21 
controls, 11 
depressed/fatigu
ed patients 
without IBS 
Caecum 
Increased in IBS, 
unchanged in 
depressed/fatigu
ed patients w/o 
IBS 
Anti-CD-
117 
NA 
In IBS, but 
not in controls 
or depressed 
patients, mast 
cell counts 
correlated 
with the 
severity of 
fatigue and 
depression 
60 
29 IBS and 15 
controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
Increased 
tryptase, 
histamine 
and PGE2 
release 
NA 78 
18 IBS and 12 
controls and 4 
UC and 1 CD 
Rectum and 
ascending 
colon 
No change 
Alcian 
blue 
staining 
and anti-
tryptase 
Increased 
trypsin 
and 
tryptase 
protein 
NA 79 
20 IBS-D and 14 
controls 
Jejunum Increased counts CD-117 
Increased 
tryptase 
release 
No correlation 
between mast 
cell counts 
62 
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and gender or 
stress levels 
20 IBS-D, 18 
IBS-C, and 20 
controls 
Descending 
part of the 
duodenum, 
proximal 
end of 
jejunum and 
terminal 
ileum 
Increased counts 
in IBS-C and 
IBS-D in ileum 
but not 
duodenum or 
jejeunum 
Anti-
tryptase 
Decreased 
5-HT 
contents at 
the 
jejunum in 
IBS-C 
patients 
NA 130 
18 IBS-D and 15 
controls 
Terminal 
ileum, 
ascending 
colon and 
rectum 
Increased in the 
terminal ileum, 
ascending colon 
and rectum 
Anti-
tryptase 
Electron 
microscop
y 
NA 
Activated 
mast cells 
were 
significantly 
closer to the 
nerves in IBS  
No correlation 
between mast 
cell counts 
and 
abdominal 
pain, urgency, 
depression 
scores and 
STAI-S/T; 
The increase 
in mucosal 
mast cell 
count in the 
terminal ileum 
was 
significantly 
associated 
with that in 
the ascending 
colon and 
rectum 
57 
44 IBS and 22 
controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
Increased 
tryptase 
and 
histamine 
release 
Vicinity of 
mast cells to 
nerves 
correlated 
with both 
severity and 
frequency of 
abdominal 
pain/discomfo
rt 
7 
28 PI-IBS, 28 
patient controls 
and 34 healthy 
volunteers 
Rectum No change 
Anti-
tryptase 
NA NA 63 
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42 IBS-D, 11 
IBS-C, 20 IBS-
A, 4 unknown 
IBS subtype and 
28 controls 
Ascending 
colon, 
transverse 
colon, 
descending 
colon, and 
rectum 
No change 
Anti-
tryptase 
NA NA 48 
10 IBS and 15 
controls 
Jejunum 
(full 
thickness) 
No change 
Giemsa 
staining 
NA NA 131 
21 PI-IBS and 12 
controls 
Rectum No change 
Anti-
tryptase 
NA NA 132 
14 IBS, 7 normal 
controls and 7 
inflammatory 
controls 
Caecum, 
ascending 
colon, 
descending 
colon and 
rectum 
Increased 
numbers in 
caecum but not 
at other sites 
Anti-
tryptase 
NA NA 50 
 
FD: functional dyspepsia, IBS: irritable bowel syndrome, IBD: inflammatory bowel 
disease, UC: ulcerative colitis, CD: Crohn’s Disease, MC: microscopic colitis, VIP: 
Vasoactive intestinal peptide, NA: Not assessed 
 
Table 3. Conditions that may alter, commonly increase, the number of mast cell counts in 
the gastrointestinal tract 
Allergic diseases: chronic urticaria, food allergy, atopy, hereditary angioedema11,98  
Mastocytosis and mast cell activation syndrome52 
Celiac disease: increased in initial stages and decreased in later stages133 
Neuroendocrine cancer, lymphoma, epithelial cancers, carcinoid syndrome 
H. Pylori gastritis, infectious and parasitic enteritis,  
Inflammatory bowel disease134, lymphocytic colitis48  
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Intestinal pseudo-obstruction, diverticulitis135 
Vasculitis, amiloidosis, drugs 
 
Table 4. Effect of mast cell mediators on gastrointestinal function 
Mediator Receptor IBS/cell type Effect Referenc
e Histamine H1R IBS-C; IBS-D Excite rat mesenteric afferents  78 
   Excite murine DRG neurons 78 
 H1-H3R IBS-C; IBS-D Excite human submucosal neurons 80 
 - - Epithelial secretion of Cl- and H2O 
136 
Tryptase PAR2 IBS-C; IBS-D Sensitize/activate murine DRG 78 
  IBS-C; IBS-D Excite human submucosal neurons 80 
  IBS-D but not Sensitization murine colonic DRG 88 
  IBS-D, IBS-A Increase epithelial permeability 137 
Serotonin 5HT3R IBS-C; IBS-D Excite human submucosal neurons 80 
  T84 cells Secretory response 138 
PGD2 DP1 IBS-C and IBS-D Excite guinea pig longitudinal 87 
 - - Epithelial secretion of Cl- and H2O 
136 
Chymase PAR2 Caco BBe Increase epithelial permeability 94 
IBS-C: constipation-predominant irritable bowel syndrome; IBS-D: diarrhea-predominant 
IBS; IBS-A: alternating subtype of IBS; H1R: Histamine receptor 1; PAR2: proteinase-
activated receptor 2; 5HT3R: 5-hydroxytriptamine receptor 3; PGD2: prostaglandin D2; 
DP1: PGD2 receptor; 
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Figure legends 
Figure 1. Ultrastructure of human mucosal mast cell. (A) Ultrastructure of an activated 
mast cell in the intestinal mucosa, with irregular plasma membrane and numerous lipid 
bodies (arrow) and cytoplasmic granules, displaying piecemeal degranulation. Intact (white 
arrowhead) and degranulated (black arrowhead) granules are identified. (B,C) High-
magnification micrographs of cytoplasmic granules from a mucosal mast cell. Different 
granule patterns are observed, with crystalloid structure (B) and scrolls (arrow, C). 
Enlarged empty and partially empty granule containers (black arrowhead) are typical of 
piecemeal degranulation. Bars: 1µm (A) and 0.5µm (B, C). 
Figure 2. Schematic representation of the experimental procedure to assess mucosal 
mast cell activation. Mast cell activation can be measured in intestinal samples. Luminal 
content can be obtained by aspiration, before biopsies are collected, and tryptase content 
can be quantified. Different mucosal biopsies can be processed for: histological 
examination, including mast cell counting after immunohistochemistry (tryptase and/or c-
kit staining) and laser microdisection for ulterior gene expression analysis; ultrastructure 
analysis, to assess the type and degree of degranulation and to identify granule pattern; 
gene expression analysis of specific mediators synthesized and released by mast cells 
(tryptase, carboxypeptidase, chymase); quantification of mediators that are spontaneously 
released from biopsies and/or performing functional studies in vitro (muscle/nervous cells) 
or in vivo (mice/rats); and electrophysiology experiments in Ussing chambers for 
identification of mast cell-dependent changes in barrier function. Finally, analysis of the 
possible association between clinical manifestations and mast cell activation can be 
performed. 
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Figure 3. Schematic illustration of mast cell-nerve interactions in human gut. 
MCs and nerves communicate bidirectionally, thereby modulating peristalsis and pain 
signalling. The release of bioactive, pro-inflammatory, mediators by mast cells results in a 
variety of neuronal effects including activation, sensitization and recruitment of nociceptors 
to the cell membrane, neurogenic inflammation and neural sprouting, ultimately leading to 
visceral hypersensitivity. On the other hand, neuronal activation triggers the release of 
neuropeptides and neurotransmitters, thereby further activating mast cells. 
Ig, immunoglobulins; TLR, toll-like receptor; NK1, neurokinin 1 receptor, PGs, 
prostaglandins; NGF, neuronal growth factor, H1R, histamine receptor 1; TRPV1, transient 
receptor potential vanilloid 1; 5-HT3, 5-hydroxytryptamine receptor 3; PAR2, proteinase-
activated receptor-2; TrkA, receptor for nerve growth factor; SP, substance P; CRGP, 
calcitonin-related gene peptide. 
Figure 4. Intestinal barrier function elements and mast cell interactions in the 
intestinal mucosa. Illustration of the potential mast cell interactions in the regulation of 
barrier function, including epithelial permeability (through TJ modulation and secretory 
response), recruitment and activation of other immunocytes, endothelial functions (vascular 
permeability and blood flow), peristalsis, and pain signalling through bidirectional 
communication with the nervous system. TJ, tight junction; AJ, adherens junction; D, 
desmosome; PAR2, proteinase-activated receptor-2; 5HT3R, 5-hydroxytryptamine receptor; 
TNFα, tumor necrosis factor alpha; ILs, interleukins; SCF, stem cell factor; GM-CSF, 
granulocyte and monocyte colony stimulating factor; IFNγ, interferon gamma; Igs, 
immunoglobulins; LT, leukotrienes; PGD2, prostaglandin D-2; CRF, corticotropin-
releasing factor; CRFR1/2, CRF receptors 1 and 2; IgE, Immunoglobulin E; IgG, 
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Immunoglobulin G; IgLC, immunoglobulin free-light chains; TLR, toll-like receptor; CNS, 
central nervous system; ENS, enteric nervous system.   
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Introduction 
Functional gastrointestinal disorders (FGIDs) are characterized by chronic complaints 
arising from disorganized brain-gut interactions leading to dysmotility and hypersensitivity. 
FGIDs diagnosis is made by symptom-based approach using the corresponding Rome 
criteria. Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are the two most 
prevalent FGIDs, affecting up to 16-26% of worldwide population1,2. However, despite 
these figures, their etiopathogenic mechanisms remain unclear, accounting for the lack of 
diagnostic biomarkers and the paucity of therapeutic options providing satisfactory long-
standing clinical remission3.  
FGIDs are associated with a high prevalence of psychiatric comorbidities, chronic fatigue 
and chronic somatic and visceral pain disorders, rendering substantial social, humanistic 
and direct and indirect health care costs4. Recent observations revealing the presence of 
low-grade mucosal inflammation and immune activation, in association with impaired 
epithelial barrier function5,6 and aberrant neuronal sensitivity come to challenge the 
traditional view of FGIDs as pure functional disorders, and relate the origin to a tangible 
organic substrate that stimulates the search for innovative diagnostic and therapeutic 
approaches. Mast cells (MCs), eosinophils and intraepithelial lymphocytes dominate the 
inflammatory infiltrate in the intestine of FGIDs. MC activation can generate epithelial and 
neuro-muscular dysfunction and promote visceral hypersensitivity and altered motility 
patterns in FGIDs7,8,9, postoperative ileus, food allergy and inflammatory bowel disease 
(IBD)10. This review will discuss the role of mucosal MCs in the gastrointestinal (GI) tract 
with a specific focus on recent advances in disease mechanisms and management in IBS 
and FD. 
The origin, phenotypes, and function of gastrointestinal MCs 
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MCs are long-lived granulated cells derived from bone marrow myeloid-cell progenitors 
(CD34+), under the influence of stem cell factor and interleukin (IL)-4, cytokines that also 
regulate the development of MCs subtypes11. MC progenitor cells (CD34+, CD13+, c-kit+, 
FcεRI-) circulate in low numbers in the blood and migrate to locate in close proximity to 
blood and lymphatic vessels, glands, smooth muscle, and nerves. In the tissue, they remain 
as a homeostatic pool or they complete their differentiation process into mature MCs, as a 
direct consequence of genetic background, and inflammatory or bacterial-derived 
molecules released in the local micro-environment including IL-3, IL-4, IL-9, IL-10, IL-33, 
CXCL12, transforming growth factor-β, nerve growth factor (NGF), and stem cell factor12. 
Intestinal homing of MCs progenitor cells depends mostly on the binding of α4β7 integrin 
with their corresponding adhesion molecules such as cell adhesion molecule-1 or vascular 
cell adhesion molecule-1 on the endothelium, although the CXC chemokine receptor 2, 
expressed on MC progenitors, has been also implicated13. Mature MCs are particularly 
abundant in body barriers, ready for optimal interaction with the local environment. In the 
GI tract, MCs comprise 1-5% of mononuclear cells in the lamina propria and the 
submucosa, and are also found intraepithelial and deep in the muscle and serosal layers. 
Based on the anatomical location, human MCs are classified into mucosal MCs and 
connective tissue MCs, while depending on protease content, MCs are divided in two large 
subsets: MCT, containing tryptase but little or no chymase, and MCTC, containing tryptase, 
chymase, and carboxypeptidase12,13. MCC, which express chymase but little or no tryptase 
also have been described, but they appear to be infrequent12,13. MCT prevail in the intestinal 
and pulmonary mucosa, near T cells, whereas MCTC are found in the skin and lymph nodes, 
in addition to the lung and the gut submucosa11. In the human small intestine, MCT 
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represent ~98% of all MCs in the mucosa and ~13% of MCs in the submucosa are MCT
12
. 
Recently, a new phenotype of MCs expressing tryptase and carboxypeptidase A3, but not 
chymase, has been described in the airway epithelium in asthmatic subjects and in 
esophageal samples of patients with eosinophilic esophagitis14. Heterogeneity of MCs also 
includes differential content in heparin, cytokines, and the receptor for the complement 
C5a, and the trans-differentiation between subtypes12,13. Therefore, location and granule 
content will determine the nature of mediators released to the extracellular milieu, 
accounting for modulation of specific functions in the GI tract11  
MCs have been viewed, for the most part, as effectors of allergy and anaphylaxis and are 
best known for their association with pathological conditions such as asthma. However, the 
advent of MC lines, mouse strains deficient in MCs, and the reconstitution of these strains 
with bone marrow-derived MCs, has greatly facilitated the characterization of various 
aspects of MC function in vivo and their involvement in several disease states by 
interacting with a variety of other cells implicated in physiological and immunological 
responses. In the GI tract, MCs regulate vascular and epithelial permeability, ion secretion, 
angiogenesis, peristalsis, fibrosis and tissue repair, innate and adaptive immunity, bacterial 
defence, chemotaxis, and nociception11. Hence, uncontrolled or dysregulated MC activation 
may interfere with gut homeostasis and generate tissue dysfunction and promote 
inflammation in diverse GI diseases such as food allergy, IBD, postoperative ileus,, 
autoimmune disorders, cancer, and FGIDs11. However, at the same time, MCs are 
indispensable for controlling a wide range of pathogenic infections, and for modulation 
innate and adaptive immune responses15. Indeed, MCs can be intentionally activated to 
enhance protective host responses, including the production of high-affinity antibodies and 
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immunological memory, raising the possibility of incorporating MC activators in vaccine 
formulations to harness the inherent adjuvant activity of MC activation15. 
Regulation and activation of MCs 
The classical and most effective stimulus for MC activation is crosslinking of cell surface-
bound IgE to its high-affinity receptor (FcεRI) by allergen in sensitized individuals16. This 
results in a sequence of phosphorylation cascades and activation motifs that leads to 
intracellular calcium flux, activation of certain transcription factors such as AP-1 (c-FOS, 
v-Jun), MITF and STAT-5, and MC degranulation and cytokine production17. MCs also 
express receptors for IgG (FcγRI), immunoglobulin free-light chains (IgLC), other Ig-
associated receptors, complement fractions, and toll-like receptors (TLRs). Moreover, MCs 
can be activated by neurotransmitters, neuropeptides, growth factors, and hormones (Table 
1), accounting for MC versatility. Upon activation, MCs release newly synthesized (lipid 
mediators and cytokines) and stored (histamine, heparin, proteases) bioactive substances 
contained in cytoplasmic lipid bodies and granules (Figure 1). Secretion is achieved by 
IgE-mediated rapid release of all granule contents by fusion of granules and extrusion 
(anaphylactic degranulation) or by partial or total granule emptying without inter-granule 
fusion (piecemeal degranulation)18. Neuropeptides, cytokines, and microbial products 
induce piecemeal degranulation as frequently seen in diverse diseases, including IBD, IBS 
and FD19.  
Factors and mechanisms underlying MC activation in the gut 
Food antigens as trigger for MC activation  
The majority of FGIDs patients consider their symptoms to be related to meals. For 
example, more than 60% of patients with IBS report the onset or worsening of symptoms 
after meals, within 15 min in 28% and within 3 h in 93% of these patients20,21. Classically, 
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in food allergy, MCs are activated by food antigen-dependent cross-linking of antigen-
specific IgE to FcƐRI. Although some patients with IBS have a higher incidence of atopy22, 
food allergy has not convincingly been associated to FGIDs pathogenesis. Of note, adverse 
reactions to food, including some types of food intolerance, may occur through IgG-
mediated sensitization of MCs but the role for these IgG-mediated immune reactions 
remains to be established20,22. When candidate food antigens are directly applied to the 
duodenal mucosa of IBS patients with suspected food intolerance through an endoscope it 
caused immediate epithelial breaks, increased intervillous spaces, and increased IEL 
numbers in the intestinal mucosa23, and an individualized exclusion diet improved 
symptoms in 74% of patients at 1 year follow-up. The underlying mechanism and the 
potential role for mast cells, requires further study. On the other hand, the response to food 
is also partly regulated by neuroendocrine factors including peripheral serotonergic 
responses24. Although MCs can secrete and synthesize serotonin from tryptophan and 
serotonin is a chemotactic molecule for MCs25, and some adverse reactions to diet in 
FGIDs involve foods containing serotonin, including cheese, meat, soya beans, cereals, nuts 
and vegetables26, the role of MCs in such responses, if any, is mostly ignored. Finally, spice 
intake correlates directly with the likelihood of developing IBS in females27. Spicy foods 
contain capsaicin, the natural ligand of transient receptor potential vanilloid 1 (TRPV1) 
receptors on nociceptive afferent C-fibers. The increased density of sensory fibers 
expressing TRPV1 receptors reported in patients with FGIDs and visceral 
hypersensitivity28, the genetic polymorphism of TRPV1 gene in FD29, the potential TRPV1 
sensitization in IBS patients30, the close proximity of MCs to TRPV1 expressing sensory 
nerve fibers, and the ability of capsaicin to modulate MCs31 all suggest that transmission of 
pain signals, including those generated by spicy foods, may be enhanced in FGIDs. In 
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contrast, desensitization of afferent terminals by a high capsaicin diet seems also plausible, 
as one study reported beneficial effects on abdominal bloating and pain in response to the 
ingestion of encapsulated red pepper for 6 weeks in IBS32. 
The role of infections 
Post-infectious (PI)-FGIDs represent common entities in daily clinical practice. Infectious 
gastroenteritis is associated with an increased risk for FD and IBS, however the 
mechanisms leading to chronicity remain unknown33. MCs are potential regulatory linkers 
between innate and adaptive immunity and have been demonstrated to play critical roles in 
host defense, participating in effective immune responses to a number of bacterial, 
parasitic, viral and fungal pathogen products15. Antibody titers against bacterial flagellin 
are increased in IBS patients and are even higher in PI-IBS34. Recently, increased mucosal 
Ig production and up-regulation of germline transcripts and Ig genes have been identified in 
diarrhea predominant IBS (IBS-D) together with increased proximity between MC and 
plasma cell, suggesting MC activation by Ig35. Whether FGIDs individuals may become 
sensitized to food and microbial antigens during an acute infection and subsequently 
develop antibodies that will activate MCs upon antigen exposure remains to be established.  
The role of stress 
Chronic stress may also lead to MC activation. In preclinical studies, several types of 
stresses and stress mediators such as corticotropin releasing hormone (CRF) and related 
peptides have been shown to modulate ion and water secretion as well as intestinal and 
colonic paracellular and transcellular permeability, primarily via nerve-MC interactions36,37. 
Similarly, stress-induced rectal hyperalgesia could be prevented and reversed by 
administration of a MC stabilizer38. Other studies have confirmed and extended this 
paradigm to the human intestine. Santos et al. showed that a cold stress increased jejunal 
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MC tryptase and histamine release along with intestinal water secretion39, and intestinal 
permeability, with larger responses in women with moderate levels of background stress40. 
CRF has been shown to enhance transcellular uptake of macromolecules in human colonic 
mucosa via CRF-R1 and CRF-R2 receptors located on subepithelial MCs41. More recently, 
acute psychological stress (public speech) has been shown to increase small intestinal 
permeability in humans42. This effect could be reproduced by peripheral administration of 
CRF, and blocked by the MC stabilizer disodium cromoglycate (DSCG). Preclinical 
models showed that chronic stress can induce substance P (SP) release by efferent nerves in 
the periphery, leading to CRF expression and release by intestinal eosinophils. Eosinophil-
derived CRF was then capable of activating MCs resulting in jejunal epithelial barrier 
dysfunction43. SP, NGF and sex steroids also induce the release of vasoactive mediators 
from MCs, contributing to chloride secretion, barrier dysfunction, hyperalgesia, diarrhea, 
inflammation and motility changes44,45.  
MC infiltration in the GI tract in FGIDs  
Since the description by Weston et al in 1993 on the infiltration of the terminal ileum by 
MCs in IBS46, numerous studies evaluated MC numbers in the gastrointestinal mucosa of 
FGIDs (Table 2). It is interesting to note here that the presence of low-grade intestinal 
inflammation in the gut of these patients also involves an increase in intraepithelial T 
lymphocytes, and less consistently, enterochromaffin cells, plasma cells, B lymphocytes, 
neutrophils, and other immunocytes47,48.  
MCs have been identified by metachromatic stains such as Giemsa or toluidine blue, but 
these methods have been replaced by immunohistochemistry (antibodies for c-kit (CD117) 
or tryptase)49,50,51 because it is more sensitive and specific. MC counts are comparable with 
both stains, yet CD117+ cells display a more stable membranous staining whereas tryptase+ 
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cells display cytoplasmic staining that could be influenced by cell degranulation52. FGIDs 
biopsies contain singly dispersed MCs with no aggregates52. When elevated MC counts are 
detected, it may be helpful to exclude systemic mastocytosis by staining for the low-affinity 
receptor for interleukin-2 (CD25)52. A reference range for significant increased MC counts 
is still lacking. This is partly due to the absence of agreement and standardization on the 
methodology used to count MCs, to differences in patient and control selection, inter-
individual variation, location of the biopsy, the relatively small cohort numbers for the 
majority of individual studies, and to other uncontrolled potential confounding factors 
(Table 3) [see Nasser et al for a detailed review]. The great variation in reporting mean 
mucosal MC numbers in the GI tract makes the interpretation of discriminatory cutoff 
values very complicated and currently un-interpretable according to some pathologists53. 
MC counts have been found to be normal, increased or decreased in IBS (Table 2). 
However, although the numbers vary across studies and segments, the analysis of more 
than one thousand IBS biopsies detects a mean, modest 1.2-2.5 fold increase in MC 
numbers throughout the entire gastrointestinal tract54,55. This is also true for cases of 
chronic undefined diarrhea, mostly studied in the upper small bowel and left colon, to the 
point that some pathologists debate the convenience of coining the term mastocytic 
enterocolitis for this clinical-pathological association56. A significant finding is that 
mucosal MC “hyperplasia”, when present, is not limited to the lower small intestine57-58 and 
colon59,60 but also involves the duodenum61, the jejunum62, and the rectum63. While there is 
discrepancy in IBS, available studies in FD reveal that MC numbers are significantly 
increased in the antrum and corpus of H. pylori negative FD64,65, and in the duodenum of 
FD patients (Table 2)9,61,66,67. Moreover, increased MCs have been recently reported in the 
esophagus of patients suffering noncardiac chest pain68. Even so, it is hard to dismiss the 
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physiological relevance of such “modest” increases because, on one side, similar 
incremental changes in leukocyte counts in circulating blood occur in infectious and 
inflammatory conditions, and on the other side, the magnitude of cell change is enormous if 
we consider the total mucosal surface of the gastrointestinal tract.  
When evaluating MCs in IBS subtypes, some studies show that MC hyperplasia is more 
common in IBS-D69,70 and in non-PI IBS71 than in other subtypes, though in many other 
studies this is not the case72,73,74. In contrast, MCs are increased similarly in gastric biopsies 
in PI-FD and nonspecific FD75. Moreover, others found MC numbers decreased in the 
descending colon of diarrhea and alternating predominant IBS, but not constipation 
predominant IBS compared to health51. There is also some indication that MC numbers 
remain increased compared to both non-PI IBS and controls, three years after Shigella 
infection73. Although not the scope of this review, an increased number of MCs has been 
reported in the colorectal mucosa, in the lamina propria and in the submucosa from patients 
with Crohn’s disease and ulcerative colitis10. 
The role of gender differences in MC number is unclear. Several lines of evidence indicate 
that gonadal steroids are involved in gender-related differences in tissue MC infiltration in 
the colon. This difference in the number of MCs has been described in a variety of tissues 
from rodents, such as skin, myocardium and rat colon. When specifically analyzed, some 
authors found increased MC counts in the terminal ileum, ascending and descending colon, 
and rectum of female vs male controls57,60,74 , with females showing 43% increase in the 
area occupied by MCs7, similar to observations in patients with chronic undefined 
diarrhea53, while others do not51,60,63. These data raise the hypothesis that gender-dependent 
differences in immune responses are involved in the observed higher prevalence of IBS in 
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females, in the described gender-related differences in IBS pathophysiology, and in the 
known effects of the menstrual cycle in the modulation of rectal sensitivity76. 
Differences in MC numbers in the jejunum, cecum, colon, or rectum of IBS are not 
attributable to age, stress and cortisol levels, anxiety or depression, or duration of the 
disease51,60,62,69. Although disputed, it seems that changes in MC counts cannot easily be 
explained by differences in bowel preparation7,48. The role of diet on MC counts remains to 
be established. Thus, the diagnostic utility of routine MC stains in gastrointestinal biopsies 
remains unclear and requires further investigation.  
MC activation in the gastrointestinal tract in FGIDs 
MC activation in the gastrointestinal tract may be evaluated by: 1-Morphological analysis, 
most commonly by checking ultrastructural characteristics of piecemeal or anaphylactic 
degranulation on transmission electron microscopy (TEM); 2-Measuring the spontaneous 
or stimulated release of mediators in tissue, intestinal fluid, and blood, most commonly 
tryptase and histamine, and less often hexosaminidase, carboxypeptidase A, heparin, 
chromogranin A, leukotriene E4, prostaglandin D2, and prostaglandin 9α,11βPGF2, and 
methylhistamine in urine, and; 3-The expression of related genes and proteins in the 
mucosa (Figure 2).  
Based on TEM studies, it has been shown that MCs display higher activation rates in the 
cecum and rectum in IBS-D, and that activation rates increase even more when nerve-MC 
distance is less than 2 µm59. Moreover, MCs located within 5 µm of nerve fibers were 3.1-
times more frequent in the descending colon of IBS than in controls, and there was a 150% 
increase in the number of degranulating MCs7. Furthermore, the ileal and colonic density of 
neuronal specific enolase, SP, and 5-hydroxytryptamine positively stained nerve fibres 
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increased and appeared in clusters, surrounding an increased number of MCs with no 
differences between PI and non-post-infection IBS patients73,77. 
Supernatants of mucosal biopsies of IBS patients contain increased concentrations of 
histamine, serotonin, trypsin, tryptase, prostaglandin E2, other proteases, and 
cytokines7,78,79,80. Moreover, jejunal luminal tryptase release was 5-times higher62 and the 
expression of both tryptase mRNA and protein enhanced in jejunal tissue8 in IBS-D, while 
serum tryptase remained unaltered. Tryptase protein expression was also higher in both 
postinfectious FD and nonspecific FD gastric biopsies64.  
It is interesting that λIgLC+ MCs but not IgE or IgG+ MCs are reduced in the colon of 
IBS51. This finding, together with the description of elevated serum concentrations of λ and 
κ IgFLC in IBS81, suggests that Ig light chain-mediated MC activation may be associated 
with IBS.  
Taken together, evidence indicates that the activity of MCs rather than an increased number 
is essential in the pathophysiology of FGIDs, a point that has been recently raised by 
several experts in the field.  
Linking MC infiltration and activation in the gastrointestinal tract with clinical 
manifestations in FGIDs 
Role of MCs in visceral hypersensitivity and motility changes: motor and neuronal 
activation and sensitization 
In the human gut, MCs lie in close proximity to gastrointestinal mucosal sensory nerve 
fibers containing neuropeptides, including visceral afferents expressing TRPV1 receptors82. 
This close spatial association, when coupled with MC activation, has been suggested to be 
of functional relevance for neuromuscular function and altered pain perception in response 
to insults such as infections, stress, and emotions in FGIDs47,83. Indeed, afferent innervation 
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of enteric MCs can trigger the release of histamine and mast cell protease II, mediators that 
act in a paracrine manner to elevate the sensitivity of spinal afferent terminals84. The use of 
supernatants obtained from biopsies allows studying the effect of these mediators on 
neuronal activation and sensitization. Injection of IBS-derived supernatants into rat 
mesenteric arteries evoked a marked increase in afferent nerve discharge, whereas injection 
of control supernatants had no effect79. In addition, IBS-dependent excitation of dorsal root 
ganglia (DRG) was inhibited by histamine H1 receptor blockade and serine protease 
inactivation78, underscoring the role of MC mediators in neuronal activation. These 
findings were confirmed by Buhner et al. who reported that IBS biopsy supernatants, but 
not those of healthy controls, significantly increased the spike discharge of human 
submucosal neurons. This effect was inhibited by histamine receptor (H1-H3) antagonists, 
5-HT3 receptor antagonist and protease inhibition80. Moreover, supernatants from 
hypersensitive IBS patients caused stronger activation of guinea pig enteric and mouse 
DRG neurons compared to supernatants of normosensitive patients85, indicating that 
neuronal activation responses in vitro correlate with the individual pain threshold pressure 
values. Others showed that intracolonic infusion of IBS supernatants, but not controls, 
caused increased nociception in response to colorectal distention in mice, an effect that 
could be prevented by a serine protease inhibitor and was absent in neurons lacking 
functional protease-activated receptor-2 (PAR2)79. More recently, Cenac et al. showed that 
colonic biopsies from IBS patients contain increased levels of PUFA metabolites, these are 
endogenous TRPV4 agonists, compared to healthy subjects and these increases correlated 
with pain and bloating scores86. PUFA metabolites extracted from IBS biopsies or colons of 
mice with visceral hypersensitivity activated mouse sensory neurons in vitro, by activating 
TRPV4, an effect that could be prevented by siRNA knockdown of TRPV486. Finally, 
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application of supernatants on muscle strips evoked excitatory cholinergic longitudinal 
muscle contractions of the guinea pig ileum, an effect that was not dependent on serotonin, 
proteases or histamine but was (partially) mediated by TRPV1, purinergic P2X receptors 
and prostanoid receptors87. Ballestra et al speculate that afferent nerve activation may 
induce myenteric cholinergic depolarizations, leading to altered motor function (Figure 3).  
Besides increased neuronal activation, supernatant of biopsies from IBS patients also has 
the capacity to potentiate sensory nerves. In a recent, elegant study, murine DRG neurons 
were incubated overnight with supernatants of submucosal colonic biopsies of IBS. Patch 
clamp recordings the next day revealed that the intrinsic excitability of the colonic 
nociceptive DRG neurons was increased by IBS-D supernatants. This increased excitability 
was not observed in DRG neurons lacking PAR-288. Finally, incubation of a neuronal cell 
line or rat primary myenteric neuron cultures with mucosal biopsy supernatants from IBS 
also induced long-lasting neuroplastic changes as reflected by increased NGF-dependent 
neuronal sprouting77.  
Together, these preclinical data consistently indicate that the mucosa and submucosa of IBS 
patients contains increased levels of various MC mediators that have the potential to 
activate and potentiate intrinsic and afferent neurons, thereby l ading to increased visceral 
pain perception and altered motor function that may cause diarrhea or constipation as a 
result of excessive segmental contractile colonic motor activity (Table 4). Of note, the use 
of human supernatants on animal models or isolated neurons may not completely reflect 
human physiology as MCs and enteric neurons exhibit species specificity in mediator 
release mechanisms and receptor profile16. To further assess the functional relevance and 
specificity of supernatant-mediated activation of nerve endings in the gut, it may be of great 
interest to perform live-imaging of MC-nerve signaling in human preparations or to 
Page 65 of 104
https://mc.manuscriptcentral.com/gut
Gut
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
16 
 
perform confocal endomicroscopy. The latter has recently been used to identify suspected 
food intolerance in IBS patients23. 
Role of MCs in the regulation of intestinal barrier function: secretion and permeability  
MCs contribution to barrier function was first described in animal studies in which 
increased ion secretion and transepithelial transport of macromolecules was reversed with a 
MC stabilizer89. In humans, stress induces the release of MC mediators (tryptase, 
histamine) to the intestinal lumen39 and increases intestinal permeability, which can be 
reversed by oral DSCG42. Stress can severely impact on barrier function and favour 
intestinal disease, as might be the case for FGIDs. IBS and FD patients experience high 
levels of anxiety, depression and stress3 and intestinal permeability, as measured by probe 
excretion assays, has been found altered, primarily in PI-IBS and IBS-D90. The mechanisms 
underlying epithelial barrier alterations are not fully understood, but disruption of the 
proteins that seal the paracellular space seems to play a role. Actually, in IBS, the 
expression of several tight junctions (TJ) proteins is reduced compared to controls and, in 
IBS-D, this reduction correlates with MC activation and with common clinical symptoms91. 
In FD, the altered expression of cell-to-cell adhesion proteins also correlates with impaired 
duodenal integrity and with mucosal inflammation9. MCs proximity to the epithelium 
facilitates tryptase activation of PAR-2 receptors on the basolateral side of enterocytes, 
leading to redistribution of TJ and increased paracellular permeability to macromolecules92. 
Other mediators released by MCs upon activation, such as histamine, chymase and 
prostaglandin D2, regulate epithelial chloride and water secretion and permeability93,94. 
MC-mediated intestinal barrier alterations have been also related to neuropeptides, 
neurotransmitters, hormones (vasoactive intestinal peptide, SP, NGF, estrogen, estradiol), 
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and inflammatory mediators (tumor necrosis factor-α, interferon-γ and cytokines) released 
by other immunocytes93 (Figure 4). 
Role of MCs in IBS cardinal manifestations 
MCs in close proximity to nerves in the descending colon were significantly correlated with 
severity and frequency of abdominal pain/discomfort7. In another study, mucosal MC 
infiltration was significantly associated with abdominal bloating frequency and with 
symptoms of dysmotility-like dyspepsia74. In contrast, in IBS, there was no correlation 
between severity or frequency of abdominal pain/discomfort and lamina propria area 
occupied by MCs, release of tryptase and histamine, and number of degranulated MCs per 
field7,57. IBS-D patients with rectal hypersensitivity, according to the maximally tolerable 
pressure to barostat distention, showed significantly lower counts of MCs in the terminal 
ileum, ascending colon and rectum in one study57. Park et al speculated that this 
counterintuitive finding was related to tissue desensitization by MCs mediators57. More 
recently, Braak et al found no correlation between the sensory thresholds to barostat 
distention, abdominal pain, bloating, urgency, incomplete evacuation, hard stools, loose 
stools, frequent and decreased bowel moments and flatulence and MCs counts in the 
colon51. An association between duodenal and antral MCs with pain, and postprandial 
distress syndrome, respectively, has been shown in children with FD67. 
Impaired intestinal permeability, and the expression of TJ proteins has been shown to 
correlate with pain/discomfort and/or bowel habit90,91,95,96. Interestingly, tryptase mRNA 
and protein expression in the jejunum of IBS-D patients correlated with stool frequency and 
consistency but not with abdominal pain, whereas the correlation with MC number was 
poor91.  
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Cecum MC counts correlated significantly with the fatigue and depression scores in IBS60, 
and, in some studies, there is a tendency or an association between depression and state of 
anxiety scores and the number of MCs in patients with IBS-D57. A significant correlation 
with antral mast cell densities with anxiety, depression and somatization has been reported 
in children with FD67. Moreover, the degranulation of MCs in the duodenum appears to be 
highly sensitive and specific for the identification of adult FD patients as shown by 100% 
sensitivity and specificity indicated by an area under the ROC curve of 1.0 for the optimal 
degranulation rate cutoff values of 30.2% at the duodenal bulb and 36.8% at the descending 
part of the duodenum66. 
Taken together, these findings suggest that interactions between the MCs and the enteric 
and brain-gut neural networks could be of importance in symptom perception in at least a 
subgroup of patients with FGIDs. 
Targeting MCs: implications for treatment of FGIDs 
The MC stabilizer DSCG abolished the effect of acute psychological stress on small bowel 
permeability in human subjects42. Aside from experimental studies demonstrating the 
efficacy of several MC inhibitors to decrease colonic hypersensitivity, in humans, a number 
of uncontrolled observations56, and open clinical studies with DSCG, in doses between 
600-1800g/day, suggest its clinical benefit for chronic persistent diarrhea97, allergic 
enteritis98, FD99, and IBS100,101,102. However, these studies had several limitations including 
poor design, small sample size, and selection bias. Likewise, ketotifen has been recently 
proven to increase the sensory threshold, leading to improved visceral perception, 
especially in the hypersensitivity IBS group103. Although preliminary, there is some 
indication of the clinical benefit of ketotifen and the tryptase inhibitor APC 2059 in 
ulcerative colitis104,105. Our group has recently finished an open trial (awaiting publication) 
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and a consecutive double-blind, placebo controlled, clinical assay, with prolonged (6 
months) oral administration of DSCG, with promising results in the control of main clinical 
manifestations in IBS-D patients (Gastroenterology 2015;148 (Supl 1):S-494). In addition, 
small studies have shown improvement in gastrointestinal symptoms with DSCG therapy in 
systemic mastocytosis106. However, the mechanisms by which MC stabilization could 
interfere with IBS clinical response have not been clearly delineated.  
Other interventions that block the effects of MC mediators and improve GI symptoms 
should be considered. In this sense, anti-inflammatory treatment with mesalazine appeared 
to show improvement in symptom perception in unselected IBS patients in a small proof-
of-concept randomized, double-blind, placebo-controlled trial, in which, in addition, a 36% 
decrease in MC numbers, and a reduction of the number of total immune cells, and T cells 
was observed in the colonic mucosa107. However, two subsequent large clinical trials differ 
in the clinical benefit of mesalazine in IBS108,109, and the effect of mesalazine on MC 
counts and degranulation not confirmed109. Furthermore, there was no effect of mesalazine 
on 5-HT containing enterochromaffin and CD68 cell numbers, although, there was 
significant increase in CD3 count in the mesalazine group109. In further reinforcing the role 
of MC activation in the origin of FGIDs manifestations, it is important to note that 
heartburn, cramping, nausea, abdominal pain and diarrhea are the second most common 
complaint of patients with mastocytosis, and that H2-histamine receptor antagonists have 
been quite effective in controlling these symptoms56,98,110. A recent proof-of-principle 
clinical trial confirmed the clinical relevance of these findings showing improvement of 
abdominal pain and global relief by the H1R antagonist ebastin in IBS patients 
(Gastroenterology 2013;144 (Supl 1):S-160). Palmitoylethanolamide and other inhibitors of 
cannabinoid receptors seem efficacious in controlling pain, motor disturbances and 
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inflammation in animal models through modulation of neuronal and non-neuronal cells, 
including MCs111,112. Slow-release of vitamin C may be also helpful as it increases 
degradation of histamine; and inhibits MC degranulation; in doses not superior to 750 
mg/day110. Natural flavonoids (fisetin, kaempferol, quercetin, rutin, luteolin,..) and the 
active alkaloid berberine inhibit the mediator release of MCs in vitro113 and protect 
intestinal epithelial barrier114. While some of these products have shown to be useful in 
cardiovascular health115 and cancer116, their clinical efficacy in FGIDs has not been 
established. There is some evidence of symptomatic response to specific diets in FGIDs, 
such as low FODMAP and gluten-depleted food20. However, there is no support for the role 
of MCs in this symptomatic response with the exception of the benefit after individualized 
exclusion of foods in FGIDs suffering food allergy. 
Finally, the development of more specific and safe blockers or modulators of IgE, IgG or 
other activation pathways of MC activation, including pathways involved in the selective 
release of mediators, may offer therapeutic advantages, although their benefit remains to be 
established.  
Conclusion 
Current evidence implicating MCs in the pathogenesis and pathophysiology of FGIDs, 
particularly in IBS, and the contribution of their activation and released mediators to the 
development of cardinal manifestations, such as epigastric and abdominal pain, and altered 
defecation is robust, and supports the targeting of MCs in the management in FGIDs. 
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Key points 
• Mast cells play a central pathophysiological role in IBS and possibly in FD, 
although not well defined. 
• Increased mast cell activation is a common finding in the mucosa of patients with 
FGIDs. 
• There is a need to implement standardized methods to count mast cells in the 
gastrointestinal mucosa, and to establish reference ranges of normality.  
• Evaluation of spontaneous and stimulated mast cell function and activity on 
gastrointestinal samples is recommended when available. 
• More studies are recommended to fully understand the implication of mast cells in 
the origin of clinical manifestations of these disorders, and to develop new 
management protocols. 
• Treatment with mast cell stabilizers offers a reasonably safe and promising option 
for the management of those IBS patients non-responding to conventional 
approaches, though future studies are warranted to evaluate efficacy and indications. 
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Table 1. Triggers of mast cell activation (modified from117) 
Type of stimuli Type of molecule Molecule/stimuli 
Immune Immunoglobulins IgE, IgG, free light chain-Ig 
(+antigen) 
 Other  C3a, C5a, IL-4, IL-6, IL-9, IL-
10, TNF-α, IFN-γ 
Non-immune Neurotransmitters Acetylcholine, Dopamine, 
Serotonin, Epinephrine, 
Histamine 
 Neuropeptides SP, VIP, HRP, CGRP, SS, NT, 
Bradykinin 
 Hormones ACTH, CRF, PTH, Ucn, 
Estradiol 
 Growth factors NGF, SCF, TGF-β, FGF-2, 
VEGF, PD-ECGF 
 Biological LPS, Peptidoglican, 
Micobacterium 
 Physico-chemical NO, osmotic, thermal, pH, 
humidity, trauma, pressure, 
hypoxia, radiation, free radicals 
Ig: immunoglobulin; IL: interleukin; C3a: complement component 3a; TNF-α: tumor 
necrosis factor alpha; IFN-γ: interferon gamma; SP: substance P; VIP: vasoactive intestinal 
peptide; HRP: histamine-releasing peptide; CGRP: calcitonin gene-related peptide; SS: 
somatostatin; NT: neurotensin; ACTH: adenocorticotropin hormone; CRF: corticotropin 
releasing factor; PTH: parathormone; Ucn: urocortin; NGF: nerve growth factor; SCF: stem 
cell factor; TGF-β: transforming growth factor beta; FGF-2: fibroblast growth factor-2; 
VEGF: vascular endothelial growth factor; PD-ECGF: platelet-derived endothelial cell 
growth factor; LPS: Lipopolysaccharide; NO: nitric oxide. 
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Table 2. Studies describing mast cell infiltration and activation in FD and IBS and potential 
correlation with symptoms. 
Condition and 
number of 
subjects 
Site of 
biopsy 
Mast cell 
numbers 
Mast cell  
detection  
Mast cell 
mediators  
Correlation 
with 
symptoms 
Referenc
e 
141 FD and 39 
controls 
Duodenum Increased counts 
Toluidine 
blue 
staining 
NA NA 66 
15 FD and 15 
controls 
Duodenum Increased 
Anti- 
tryptase 
NA NA 9 
19 FD and 19 
controls 
(pediatric) 
 No change 
Anti- 
tryptase 
NA 
No correlation 
between 
permeability 
and mast cell 
density 
118 
65 H. PYLORI -
negative FD 
(pediatric) 
Gastric body 
and 
duodenum 
 
Anti- 
tryptase 
NA 
Headache was 
associated 
with high 
mast cell 
counts in the 
gastric body 
and 
duodenum 
65 
51 FD, 20 IBS-D 
and 21 IBS-C 
and 48 controls 
Duodenum 
Increased counts 
in IBS-C and 
IBS-D and trend 
for increase in 
FD 
Anti-CD-
117 
NA NA 61 
62 FD (33 
Helicobacter 
pylori positive, 
29 H. pylori 
negative and 29 
H. pylori 
positive 
inflammatory 
control subjects 
and 20 controls, 
Antrum and 
corpus 
Increased in H. 
pylori negative 
and positive FD 
samples in 
antrum and 
corpus 
Anti- 
tryptase 
NA NA 64 
225 patients with 
non-ulcer 
dyspepsia 
Antrum 
31 (13%) were 
found to have 11 
or greater mast 
cells per high-
Alcian 
blue 
staining 
NA NA 119 
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power field 
Total of 101 IBS 
and 23 controls, 
for IHC: 15 
controls; 15 IBS-
C; 14 IBS-D 
Descending 
colon 
Increased counts 
Anti-
tryptase 
NA NA 77 
13 IBS-D, 8 
IBS-C and 10 
controls 
(pediatric) 
Ileum, right 
colon and 
left colon 
No change in 
numbers but 
mast cells in 
closer proximity 
to nerves in IBS 
(MC-NF/mm2) 
Anti-
tryptase 
NA 
Abdominal 
pain 
correlated 
with 
MC/mm2 in 
the ileum and 
MC-NF/mm2 
in the right 
colon 
120 
49 IBS-D and 30 
controls 
Jejunum 
Increased counts 
in non-atopic 
IBS 
Anti-CD-
117 
NA NA 35 
100 IBS and 100 
controls 
Colon, 
ileum, 
duodenum 
and stomach 
No change 
Anti-CD-
117 and 
anti-CD-
25 
NA NA 52 
55 IBS-D and 18 
controls with 
lactase 
deficiency 
Sigmoid 
colon, 
ascending 
colon and 
terminal 
ileum 
increased counts 
in the terminal 
ileum, ascending 
and sigmoid 
colon 
Anti-
tryptase 
NA 
Anxiety 
scores were 
associated 
with mast cell 
counts in 
sigmoid 
colon, 
ascending 
colon and 
terminal 
ileum.  
Visceral 
sensitivity 
(i.e. decrease 
in urgency, 
discomfort/pai
n threshold) 
was increased 
in patients 
with high 
mast cell 
density in the 
terminal ileum 
121 
22 IBS-D and 21 
controls 
Rectum 
Increased counts 
in IBS-D 
Anti-
tryptase 
NA 
Mast cell 
counts did not 
correlate with 
122 
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IBS 
symptoms 
including 
abdominal 
pain; Mast 
cell counts 
correlated 
with 
substance P 
and VIP in 
women but 
not in men 
83 D-IBS, 49 
UC (28 in 
remission and 21 
mildly active 
UC), and 25 
controls 
Ascending, 
transverse, 
descending, 
and sigmoid 
colon 
Increased counts 
in patients with 
D-IBS, UC in 
remission, and 
mildly active UC 
Anti-
tryptase 
NA NA 123 
51 IBS, 49 
quiescent IBD 
(31 CD and 18 
UC) and 27 
controls 
Caecum 
increased in 
patients with 
IBS, CD or UC 
(no difference 
between patients 
between patients 
with or without 
IBS-like 
symptoms 
Anti-CD-
117 
NA NA 124 
16 IBS-D and 7 
controls 
Rectum No change 
Anti-
tryptase 
Increased 
tryptase 
release 
Mast cell 
counts 
correlated 
with intestinal 
permeability 
125 
45 IBS-D and 30 
controls 
Jejunum Increased counts 
Anti-CD-
117 
Increased 
tryptase 
mRNA 
and 
protein 
Tryptase 
mRNA 
expression but 
not mast cell 
counts 
correlated 
with stool 
frequency and 
consistency in 
IBS-D 
patients; 
tryptase 
protein 
expression 
correlated 
CLDN2 
protein 
overexpressio
n and 
increased 
8 
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OCLN 
cytoplasmic 
staining 
16 IBS-D, 21 C-
IBS and 11 
controls 
Descending 
colon 
Increased counts 
in IBS-C but not 
IBS-D 
Anti-
tryptase 
NA 
Mast cell 
counts of IBS 
but not 
controls 
correlated 
with the 
twitch 
enhancement 
evoked by 
biopsy 
supernatants 
87 
34 IBS and 15 
controls 
Rectum Increased counts 
Anti-CD-
117 
Increased 
tryptase 
release 
IBS severity 
correlated 
with colonic 
permeability, 
mast cell 
counts and 
tryptase 
95 
4 IBS-C, 11 IBS-
D, 8 IBS-A and 
15 controls 
Colorectum No change 
Anti-
tryptase 
NA NA 126 
11 IBS-D and 14 
controls 
(pediatric) 
Rectum No change 
Anti-
tryptase 
and anti-
CD-117 
NA NA 127 
15 IBS-D, 15 
IBS-C, 36 IBS-A 
and 20 controls 
Descending 
colon 
decreased mast 
cell counts 
Anti-CD-
117 
NA 
No correlation 
between the 
the number of 
mast cells and 
abdominal 
pain or 
sensory 
thresholds of 
first sensation, 
urge or 
discomfort 
and 
51 
25 IBS-D and 23 
controls 
Jejunum Increased counts 
Anti-CD-
117 
Increased 
tryptase 
mRNA 
Tryptase and 
SCF 
correlated 
with tight 
junction ZO 
protein 
expression. 
Bowel 
frequency and 
91 
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stool 
consistency 
correlated 
with both the 
number of 
mast cells and 
tryptase 
mRNA 
expression,  
and with the 
expression of 
ZO proteins 
12 IBS-C, 13 
IBS-D and 12 
controls 
Desce ding 
colon 
Increased counts 
Anti-
tryptase 
Increased 
serotonin, 
histamine 
and 
tryptase 
release 
irrespectiv
e of bowel 
habit 
5-HT release 
correlated 
with mast cell 
counts and the 
severity of 
abdominal 
pain 
128 
60 IBS and 22 
controls 
Rectum and 
descending 
colon  
decreased mast 
cell counts in 
rectal biopsies 
Anti-
tryptase 
and anti-
CD117 
Lower 
release of 
tryptase, 
slight 
increase in 
histamine 
release 
The severity 
of abdominal 
pain was not 
correlated 
with mast cell 
counts; no 
correlation 
between 
abdominal 
pain and 
spontaneous 
histamine or 
tryptase 
release 
103 
13 IBS-D, 8 
IBS-C, 4 IBS-A, 
10 active CD and 
18 controls 
Descending 
colon 
Increased counts 
in IBS-D but not 
in IBS-C 
Anti-CD-
117 
Increased 
trypsin-
like 
protein  
NA 129 
27 IBS-D, 21 
IBS-C, 12 MC 
20 UC, and 24 
controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
NA 
Mast cell 
counts in IBS 
patients was 
associated 
with 
abdominal 
bloating 
frequency and 
with 
symptoms of 
dysmotility-
like 
dyspepsia, but 
74 
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not ulcer-like 
dyspepsia 
7 IBS-D, 4 IBS-
C and 4 controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
Increased 
tryptase 
and 
histamine 
release but 
not 
serotonin 
Association 
between the 
number of 
mast cells and 
the 
corresponding 
supernatant-
evoked spike 
frequency. 
Tryptase, 
histamine and 
serotonin 
concentrations 
all correlated 
with the 
supernatant-
evoked action 
potential 
discharges. 
80 
8 IBS-D, 8 IBS-
C, 7 IBS-A and 
22 controls 
Rectosigmoi
d 
Increased counts 
Anti-CD-
117 
NA 
c-kit+ cells 
correlated 
with maximal 
VAS pain 
score 
28 
50 IBS, 21 
controls, 11 
depressed/fatigu
ed patients 
without IBS 
Caecum 
Increased in IBS, 
unchanged in 
depressed/fatigu
ed patients w/o 
IBS 
Anti-CD-
117 
NA 
In IBS, but 
not in controls 
or depressed 
patients, mast 
cell counts 
correlated 
with the 
severity of 
fatigue and 
depression 
60 
29 IBS and 15 
controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
Increased 
tryptase, 
histamine 
and PGE2 
release 
NA 78 
18 IBS and 12 
controls and 4 
UC and 1 CD 
Rectum and 
ascending 
colon 
No change 
Alcian 
blue 
staining 
and anti-
tryptase 
Increased 
trypsin 
and 
tryptase 
protein 
NA 79 
20 IBS-D and 14 
controls 
Jejunum Increased counts CD-117 
Increased 
tryptase 
release 
No correlation 
between mast 
cell counts 
62 
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and gender or 
stress levels 
20 IBS-D, 18 
IBS-C, and 20 
controls 
Descending 
part of the 
duodenum, 
proximal 
end of 
jejunum and 
terminal 
ileum 
Increased counts 
in IBS-C and 
IBS-D in ileum 
but not 
duodenum or 
jejeunum 
Anti-
tryptase 
Decreased 
5-HT 
contents at 
the 
jejunum in 
IBS-C 
patients 
NA 130 
18 IBS-D and 15 
controls 
Terminal 
ileum, 
ascending 
colon and 
rectum 
Increased in the 
terminal ileum, 
ascending colon 
and rectum 
Anti-
tryptase 
Electron 
microscop
y 
NA 
Activated 
mast cells 
were 
significantly 
closer to the 
nerves in IBS  
No correlation 
between mast 
cell counts 
and 
abdominal 
pain, urgency, 
depression 
scores and 
STAI-S/T; 
The increase 
in mucosal 
mast cell 
count in the 
terminal ileum 
was 
significantly 
associated 
with that in 
the ascending 
colon and 
rectum 
57 
44 IBS and 22 
controls 
Descending 
colon 
Increased counts 
Anti-
tryptase 
Increased 
tryptase 
and 
histamine 
release 
Vicinity of 
mast cells to 
nerves 
correlated 
with both 
severity and 
frequency of 
abdominal 
pain/discomfo
rt 
7 
28 PI-IBS, 28 
patient controls 
and 34 healthy 
volunteers 
Rectum No change 
Anti-
tryptase 
NA NA 63 
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42 IBS-D, 11 
IBS-C, 20 IBS-
A, 4 unknown 
IBS subtype and 
28 controls 
Ascending 
colon, 
transverse 
colon, 
descending 
colon, and 
rectum 
No change 
Anti-
tryptase 
NA NA 48 
10 IBS and 15 
controls 
Jejunum 
(full 
thickness) 
No change 
Giemsa 
staining 
NA NA 131 
21 PI-IBS and 12 
controls 
Rectum No change 
Anti-
tryptase 
NA NA 132 
14 IBS, 7 normal 
controls and 7 
inflammatory 
controls 
Caecum, 
ascending 
colon, 
descending 
colon and 
rectum 
Increased 
numbers in 
caecum but not 
at other sites 
Anti-
tryptase 
NA NA 50 
 
FD: functional dyspepsia, IBS: irritable bowel syndrome, IBD: inflammatory bowel 
disease, UC: ulcerative colitis, CD: Crohn’s Disease, MC: microscopic colitis, VIP: 
Vasoactive intestinal peptide, NA: Not assessed 
 
Table 3. Conditions that may alter, commonly increase, the number of mast cell counts in 
the gastrointestinal tract 
Allergic diseases: chronic urticaria, food allergy, atopy, hereditary angioedema11,98  
Mastocytosis and mast cell activation syndrome52 
Celiac disease: increased in initial stages and decreased in later stages133 
Neuroendocrine cancer, lymphoma, epithelial cancers, carcinoid syndrome 
H. Pylori gastritis, infectious and parasitic enteritis,  
Inflammatory bowel disease134, lymphocytic colitis48  
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Intestinal pseudo-obstruction, diverticulitis135 
Vasculitis, amiloidosis, drugs 
 
Table 4. Effect of mast cell mediators on gastrointestinal function 
Mediator Receptor IBS/cell type Effect Referenc
e Histamine H1R IBS-C; IBS-D Excite rat mesenteric afferents  78 
   Excite murine DRG neurons 78 
 H1-H3R IBS-C; IBS-D Excite human submucosal neurons 80 
 - - Epithelial secretion of Cl- and H2O 
136 
Tryptase PAR2 IBS-C; IBS-D Sensitize/activate murine DRG 78 
  IBS-C; IBS-D Excite human submucosal neurons 80 
  IBS-D but not Sensitization murine colonic DRG 88 
  IBS-D, IBS-A Increase epithelial permeability 137 
Serotonin 5HT3R IBS-C; IBS-D Excite human submucosal neurons 80 
  T84 cells Secretory response 138 
PGD2 DP1 IBS-C and IBS-D Excite guinea pig longitudinal 87 
 - - Epithelial secretion of Cl- and H2O 
136 
Chymase PAR2 Caco BBe Increase epithelial permeability 94 
IBS-C: constipation-predominant irritable bowel syndrome; IBS-D: diarrhea-predominant 
IBS; IBS-A: alternating subtype of IBS; H1R: Histamine receptor 1; PAR2: proteinase-
activated receptor 2; 5HT3R: 5-hydroxytriptamine receptor 3; PGD2: prostaglandin D2; 
DP1: PGD2 receptor; 
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Figure legends 
Figure 1. Ultrastructure of human mucosal mast cell. (A) Ultrastructure of an activated 
mast cell in the intestinal mucosa, with irregular plasma membrane and numerous lipid 
bodies (arrow) and cytoplasmic granules, displaying piecemeal degranulation. Intact (white 
arrowhead) and degranulated (black arrowhead) granules are identified. (B,C) High-
magnification micrographs of cytoplasmic granules from a mucosal mast cell. Different 
granule patterns are observed, with crystalloid structure (B) and scrolls (arrow, C). 
Enlarged empty and partially empty granule containers (black arrowhead) are typical of 
piecemeal degranulation. Bars: 1µm (A) and 0.5µm (B, C). 
Figure 2. Schematic representation of the experimental procedure to assess mucosal 
mast cell activation. Mast cell activation can be measured in intestinal samples. Luminal 
content can be obtained by aspiration, before biopsies are collected, and tryptase content 
can be quantified. Different mucosal biopsies can be processed for: histological 
examination, including mast cell counting after immunohistochemistry (tryptase and/or c-
kit staining) and laser microdisection for ulterior gene expression analysis; ultrastructure 
analysis, to assess the type and degree of degranulation and to identify granule pattern; 
gene expression analysis of specific mediators synthesized and released by mast cells 
(tryptase, carboxypeptidase, chymase); quantification of mediators that are spontaneously 
released from biopsies and/or performing functional studies in vitro (muscle/nervous cells) 
or in vivo (mice/rats); and electrophysiology experiments in Ussing chambers for 
identification of mast cell-dependent changes in barrier function. Finally, analysis of the 
possible association between clinical manifestations and mast cell activation can be 
performed. 
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Figure 3. Schematic illustration of mast cell-nerve interactions in human gut. 
MCs and nerves communicate bidirectionally, thereby modulating peristalsis and pain 
signalling. The release of bioactive, pro-inflammatory, mediators by mast cells results in a 
variety of neuronal effects including activation, sensitization and recruitment of nociceptors 
to the cell membrane, neurogenic inflammation and neural sprouting, ultimately leading to 
visceral hypersensitivity. On the other hand, neuronal activation triggers the release of 
neuropeptides and neurotransmitters, thereby further activating mast cells. 
Ig, immunoglobulins; TLR, toll-like receptor; NK1, neurokinin 1 receptor, PGs, 
prostaglandins; NGF, neuronal growth factor, H1R, histamine receptor 1; TRPV1, transient 
receptor potential vanilloid 1; 5-HT3, 5-hydroxytryptamine receptor 3; PAR2, proteinase-
activated receptor-2; TrkA, receptor for nerve growth factor; SP, substance P; CRGP, 
calcitonin-related gene peptide. 
Figure 4. Intestinal barrier function elements and mast cell interactions in the 
intestinal mucosa. Illustration of the potential mast cell interactions in the regulation of 
barrier function, including epithelial permeability (through TJ modulation and secretory 
response), recruitment and activation of other immunocytes, endothelial functions (vascular 
permeability and blood flow), peristalsis, and pain signalling through bidirectional 
communication with the nervous system. TJ, tight junction; AJ, adherens junction; D, 
desmosome; PAR2, proteinase-activated receptor-2; 5HT3R, 5-hydroxytryptamine receptor; 
TNFα, tumor necrosis factor alpha; ILs, interleukins; SCF, stem cell factor; GM-CSF, 
granulocyte and monocyte colony stimulating factor; IFNγ, interferon gamma; Igs, 
immunoglobulins; LT, leukotrienes; PGD2, prostaglandin D-2; CRF, corticotropin-
releasing factor; CRFR1/2, CRF receptors 1 and 2; IgE, Immunoglobulin E; IgG, 
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Immunoglobulin G; IgLC, immunoglobulin free-light chains; TLR, toll-like receptor; CNS, 
central nervous system; ENS, enteric nervous system.   
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Figure 1. Ultrastructure of human mucosal mast cell. (A) Ultrastructure of an activated mast cell in the 
intestinal mucosa, with irregular plasma membrane and numerous lipid bodies (arrow) and cytoplasmic 
granules, displaying piecemeal degranulation. Intact (white arrowhead) and degranulated (black arrowhead) 
granules are identified. (B,C) High-magnification micrographs of cytoplasmic granules from a mucosal mast 
cell. Different granule patterns are observed, with crystalloid structure (B) and scrolls (arrow, C). Enlarged 
empty and partially empty granule containers (black arrowhead) are typical of piecemeal degranulation. 
Bars: 1µm (A) and 0.5µm (B, C).  
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Figure 2. Schematic representation of the experimental procedure to assess mucosal mast cell activation. 
Mast cell activation can be measured in intestinal samples. Luminal content can be obtained by aspiration, 
before biopsies are collected, and tryptase content can be quantified. Different mucosal biopsies can be 
processed for: histological examination, including mast cell counting after immunohistochemistry (tryptase 
and/or c-kit staining) and laser microdisection for ulterior gene expression analysis; ultrastructure analysis, 
to assess the type and degree of degranulation and to identify granule pattern; gene expression analysis of 
specific mediators synthesized and released by mast cells (tryptase, carboxypeptidase, chymase); 
quantification of mediators that are spontaneously released from biopsies and/or performing functional 
studies in vitro (muscle/nervous cells) or in vivo (mice/rats); and electrophysiology experiments in Ussing 
chambers for identification of mast cell-dependent changes in barrier function. Finally, analysis of the 
possible association between clinical manifestations and mast cell activation can be performed.  
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Figure 3. Schematic illustration of mast cell-nerve interactions in human gut.  
MCs and nerves communicate bidirectionally, thereby modulating peristalsis and pain signalling. The release 
of bioactive, pro-inflammatory, mediators by mast cells results in a variety of neuronal effects including 
activation, sensitization and recruitment of nociceptors to the cell membrane, neurogenic inflammation and 
neural sprouting, ultimately leading to visceral hypersensitivity. On the other hand, neuronal activation 
triggers the release of neuropeptides and neurotransmitters, thereby further activating mast cells.  
Ig, immunoglobulins; TLR, toll-like receptor; NK1, neurokinin 1 receptor, PGs, prostaglandins; NGF, 
neuronal growth factor, H1R, histamine receptor 1; TRPV1, transient receptor potential vanilloid 1; 5-HT3, 
5-hydroxytryptamine receptor 3; PAR2, proteinase-activated receptor-2; TrkA, receptor for nerve growth 
factor; SP, substance P; CRGP, calcitonin-related gene peptide.  
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Figure 4. Intestinal barrier function elements and mast cell interactions in the intestinal mucosa. Illustration 
of the potential mast cell interactions in the regulation of barrier function, including epithelial permeability 
(through TJ modulation and secretory response), recruitment and activation of other immunocytes, 
endothelial functions (vascular permeability and blood flow), peristalsis, and pain signalling through 
bidirectional communication with the nervous system. TJ, tight junction; AJ, adherens junction; D, 
desmosome; PAR2, proteinase-activated receptor-2; 5HT3R, 5-hydroxytryptamine receptor; TNFα, tumor 
necrosis factor alpha; ILs, interleukins; SCF, stem cell factor; GM-CSF, granulocyte and monocyte colony 
stimulating factor; IFNγ, interferon gamma; Igs, immunoglobulins; LT, leukotrienes; PGD2, prostaglandin D-
2; CRF, corticotropin-releasing factor; CRFR1/2, CRF receptors 1 and 2; IgE, Immunoglobulin E; IgG, 
Immunoglobulin G; IgLC, immunoglobulin free-light chains; TLR, toll-like receptor; CNS, central nervous 
system; ENS, enteric nervous system.  
178x164mm (300 x 300 DPI)  
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